|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance multiple interactions increases expression |
EXP |
ABCB1 exon polymorphism affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Celecoxib results in decreased expression of ABCB1] which results in increased susceptibility to Etoposide Etoposide results in increased expression of ABCB1 mRNA; Etoposide results in increased expression of ABCB1 protein |
CTD |
PMID:12969965 PMID:15239124 PMID:19047049 PMID:19562670 PMID:27570640 PMID:27840903 More...
|
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 (ABCC1 blood group) |
affects response to substance decreases response to substance multiple interactions decreases uptake increases expression |
EXP ISO |
ABCC1 protein affects the susceptibility to Etoposide ABCC1 protein results in decreased susceptibility to Etoposide; ABCC1 results in decreased susceptibility to Etoposide [GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Silymarin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Tocopherols inhibits the reaction [ABCC1 protein affects the export of Etoposide]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide] ABCC1 protein results in decreased uptake of Etoposide Etoposide results in increased expression of ABCC1 mRNA Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide] |
CTD |
PMID:7954421 PMID:8968083 PMID:9334814 PMID:10348353 PMID:10856430 PMID:10900222 PMID:11778547 PMID:15180633 PMID:15460906 PMID:15617835 PMID:15999103 PMID:16156793 PMID:16217747 More...
|
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects transport multiple interactions |
EXP |
ABCC2 protein affects the transport of Etoposide Probenecid promotes the reaction [ABCC2 protein affects the transport of Etoposide] |
CTD |
PMID:15751272 PMID:15849751 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
decreases response to substance |
EXP |
ABCC3 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15884115 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
EXP |
[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] |
CTD |
PMID:21712253 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ABHD4 |
abhydrolase domain containing 4, N-acyl phospholipase B |
increases expression |
ISO |
Etoposide results in increased expression of ABHD4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:22,598,300...22,612,963
Ensembl chr14:22,598,290...22,612,963
|
|
G |
ABRA |
actin binding Rho activating protein |
increases expression |
EXP |
Etoposide results in increased expression of ABRA mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:106,759,483...106,770,244
Ensembl chr 8:106,759,483...106,770,244
|
|
G |
ACADM |
acyl-CoA dehydrogenase medium chain |
affects response to substance |
EXP |
ACADM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
increases expression decreases expression |
EXP ISO |
Etoposide results in increased expression of ACE2 mRNA Etoposide results in decreased expression of ACE2 mRNA |
CTD |
PMID:29397400 PMID:32808185 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACO1 |
aconitase 1 |
increases expression |
ISO |
Etoposide results in increased expression of ACO1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:32,384,643...32,454,769
Ensembl chr 9:32,384,603...32,454,769
|
|
G |
ACSL3 |
acyl-CoA synthetase long chain family member 3 |
affects response to substance |
EXP |
ACSL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:222,861,036...222,944,639
Ensembl chr 2:222,860,942...222,944,639
|
|
G |
ACTA1 |
actin alpha 1, skeletal muscle |
decreases expression |
EXP |
Etoposide results in decreased expression of ACTA1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:229,431,245...229,434,094
Ensembl chr 1:229,430,365...229,434,104
|
|
G |
AGRN |
agrin |
increases expression |
EXP |
Etoposide results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:1,020,120...1,056,116
Ensembl chr 1:1,020,120...1,056,118
|
|
G |
AHCYL1 |
adenosylhomocysteinase like 1 |
affects response to substance |
EXP |
AHCYL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:109,984,765...110,023,742
Ensembl chr 1:109,984,765...110,023,742
|
|
G |
AHI1 |
Abelson helper integration site 1 |
increases expression |
EXP |
Etoposide results in increased expression of AHI1 protein alternative form |
CTD |
PMID:19379585 |
|
NCBI chr 6:135,283,532...135,497,740
Ensembl chr 6:135,283,407...135,498,434
|
|
G |
AKAP12 |
A-kinase anchoring protein 12 |
affects response to substance |
EXP |
AKAP12 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:151,239,967...151,358,559
Ensembl chr 6:151,239,967...151,358,559
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases response to substance increases phosphorylation multiple interactions |
EXP |
AKT1 protein modified form results in increased susceptibility to Etoposide Etoposide results in increased phosphorylation of AKT1 protein Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]; pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide]; PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:17699715 PMID:17935137 PMID:23396362 PMID:27769712 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALAD |
aminolevulinate dehydratase |
multiple interactions |
EXP |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 9:113,386,312...113,401,284
Ensembl chr 9:113,386,312...113,401,290
|
|
G |
ALAS1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Etoposide results in increased expression of ALAS1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:52,198,083...52,214,327
Ensembl chr 3:52,198,086...52,214,327
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
multiple interactions increases expression |
EXP |
FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein] Etoposide results in increased expression of ALDH1A1 mRNA; Etoposide results in increased expression of ALDH1A1 protein |
CTD |
PMID:33969609 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ALDH3A1 |
aldehyde dehydrogenase 3 family member A1 |
affects response to substance |
EXP |
ALDH3A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:15905174 |
|
NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943
|
|
G |
ALDOC |
aldolase, fructose-bisphosphate C |
affects response to substance multiple interactions |
EXP ISO |
ALDOC protein affects the susceptibility to Etoposide [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein |
CTD |
PMID:16217747 PMID:29733421 |
|
NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948
|
|
G |
ALPG |
alkaline phosphatase, germ cell |
affects response to substance |
EXP |
ALPG protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:232,406,844...232,410,714
Ensembl chr 2:232,406,844...232,410,714
|
|
G |
ALPP |
alkaline phosphatase, placental |
affects response to substance |
EXP |
ALPP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:232,378,751...232,382,889
Ensembl chr 2:232,378,724...232,382,889
|
|
G |
ANK1 |
ankyrin 1 |
increases expression |
EXP |
Etoposide results in increased expression of ANK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:41,653,225...41,896,741
Ensembl chr 8:41,653,220...41,896,741
|
|
G |
ANKRD10 |
ankyrin repeat domain 10 |
decreases expression |
EXP |
Etoposide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:110,878,540...110,915,069
Ensembl chr13:110,878,540...110,915,069
|
|
G |
ANKRD27 |
ankyrin repeat domain 27 |
decreases expression |
ISO |
Etoposide results in decreased expression of ANKRD27 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:32,597,006...32,675,180
Ensembl chr19:32,597,006...32,676,597
|
|
G |
ANKRD28 |
ankyrin repeat domain 28 |
affects response to substance |
EXP |
ANKRD28 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:15,667,236...15,859,814
Ensembl chr 3:15,667,236...15,859,771
|
|
G |
ANXA4 |
annexin A4 |
increases expression |
EXP |
Etoposide results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
|
|
G |
ANXA7 |
annexin A7 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ANXA7 protein |
CTD |
PMID:29733421 |
|
NCBI chr10:73,375,101...73,414,058
Ensembl chr10:73,375,101...73,414,076
|
|
G |
APAF1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
Etoposide results in increased expression of APAF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:98,645,290...98,735,433
Ensembl chr12:98,645,290...98,735,433
|
|
G |
APEX1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases response to substance |
EXP |
APEX1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:20856196 |
|
NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
|
|
G |
APLP1 |
amyloid beta precursor like protein 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of APLP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:35,868,574...35,879,792
Ensembl chr19:35,867,899...35,879,792
|
|
G |
APOBEC3C |
apolipoprotein B mRNA editing enzyme catalytic subunit 3C |
affects response to substance |
EXP |
APOBEC3C protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr22:39,014,257...39,020,352
Ensembl chr22:39,014,257...39,020,352
|
|
G |
AQP1 |
aquaporin 1 (Colton blood group) |
decreases expression |
ISO |
Etoposide results in decreased expression of AQP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:30,911,853...30,925,516
Ensembl chr 7:30,911,853...30,925,517
|
|
G |
AR |
androgen receptor |
multiple interactions increases degradation |
EXP |
calpain inhibitor 2 inhibits the reaction [Etoposide results in increased degradation of AR protein]; CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]; Etoposide inhibits the reaction [Androgens results in increased activity of AR protein]; Etoposide inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18726991 PMID:28377212 PMID:30818834 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
AREG |
amphiregulin |
increases expression decreases expression |
EXP ISO |
Etoposide results in increased expression of AREG mRNA; Etoposide results in increased expression of AREG protein Etoposide results in decreased expression of AREG mRNA |
CTD |
PMID:15228094 PMID:25270620 |
|
NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005
|
|
G |
ARG2 |
arginase 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of ARG2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:67,619,920...67,651,708
Ensembl chr14:67,619,920...67,651,708
|
|
G |
ARHGDIB |
Rho GDP dissociation inhibitor beta |
increases expression |
EXP |
Etoposide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr12:14,942,015...14,961,601
Ensembl chr12:14,942,031...14,961,728
|
|
G |
ARIH1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases response to substance |
ISO |
ARIH1 mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:25624349 |
|
NCBI chr15:72,474,330...72,602,987
Ensembl chr15:72,474,330...72,602,987
|
|
G |
ARL6IP5 |
ADP ribosylation factor like GTPase 6 interacting protein 5 |
increases response to substance decreases expression |
EXP |
ARL6IP5 protein results in increased susceptibility to Etoposide Etoposide results in decreased expression of ARL6IP5 |
CTD |
PMID:19492242 |
|
NCBI chr 3:69,084,937...69,106,092
Ensembl chr 3:69,084,937...69,106,092
|
|
G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708
|
|
G |
ARSA |
arylsulfatase A |
decreases expression |
ISO |
Etoposide results in decreased expression of ARSA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr22:50,622,754...50,628,152
Ensembl chr22:50,622,754...50,628,173
|
|
G |
ASAH1 |
N-acylsphingosine amidohydrolase 1 |
affects response to substance |
EXP |
ASAH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:18,055,992...18,084,961
Ensembl chr 8:18,055,992...18,084,998
|
|
G |
ATF2 |
activating transcription factor 2 |
multiple interactions |
EXP |
Etoposide results in increased phosphorylation of and results in increased activity of ATF2 protein |
CTD |
PMID:12663670 |
|
NCBI chr 2:175,072,259...175,168,203
Ensembl chr 2:175,072,250...175,168,382
|
|
G |
ATF4 |
activating transcription factor 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO EXP |
Etoposide results in increased phosphorylation of and results in increased activity of ATM protein Etoposide results in increased phosphorylation of ATM protein Etoposide results in increased phosphorylation of and affects the localization of ATM protein; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of and affects the localization of ATM protein] |
CTD |
PMID:22242153 PMID:26259609 PMID:37451322 |
|
NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102
|
|
G |
ATP13A4 |
ATPase 13A4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP13A4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:193,398,967...193,593,119
Ensembl chr 3:193,398,967...193,593,111
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
affects response to substance |
EXP |
ATP1A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:116,373,244...116,404,774
Ensembl chr 1:116,372,668...116,410,261
|
|
G |
ATP1A2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:160,115,759...160,143,591
Ensembl chr 1:160,115,759...160,143,591
|
|
G |
ATP1B4 |
ATPase Na+/K+ transporting family member beta 4 |
increases expression |
EXP |
Etoposide results in increased expression of ATP1B4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:120,362,089...120,383,237
Ensembl chr X:120,362,085...120,383,249
|
|
G |
ATP5ME |
ATP synthase membrane subunit e |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of ATP5ME protein |
CTD |
PMID:29733421 |
|
NCBI chr 4:672,436...674,276
Ensembl chr 4:672,436...674,330
|
|
G |
ATP5PO |
ATP synthase peripheral stalk subunit OSCP |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP5PO protein |
CTD |
PMID:29733421 |
|
NCBI chr21:33,903,453...33,915,804
Ensembl chr21:33,903,453...33,915,814
|
|
G |
ATP6V0A4 |
ATPase H+ transporting V0 subunit a4 |
affects response to substance |
EXP |
ATP6V0A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:138,706,294...138,798,196
Ensembl chr 7:138,706,294...138,799,560
|
|
G |
ATP6V1A |
ATPase H+ transporting V1 subunit A |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of ATP6V1A protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein |
CTD |
PMID:29733421 |
|
NCBI chr 3:113,747,035...113,812,056
Ensembl chr 3:113,746,770...113,812,056
|
|
G |
ATP7A |
ATPase copper transporting alpha |
decreases response to substance |
EXP |
ATP7A protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17510416 |
|
NCBI chr X:77,910,693...78,050,395
Ensembl chr X:77,910,690...78,050,395
|
|
G |
ATR |
ATR serine/threonine kinase |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of ATR protein |
CTD |
PMID:22242153 |
|
NCBI chr 3:142,449,235...142,578,733
Ensembl chr 3:142,449,007...142,578,733
|
|
G |
ATXN1 |
ataxin 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of ATXN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:16,299,112...16,761,460
Ensembl chr 6:16,299,112...16,761,491
|
|
G |
AURKA |
aurora kinase A |
decreases expression |
ISO |
Etoposide results in decreased expression of AURKA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:56,369,390...56,392,215
Ensembl chr20:56,369,389...56,392,337
|
|
G |
AVPI1 |
arginine vasopressin induced 1 |
affects response to substance |
EXP |
AVPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:97,677,424...97,687,241
Ensembl chr10:97,677,424...97,687,241
|
|
G |
AVPR1A |
arginine vasopressin receptor 1A |
increases expression |
EXP |
Etoposide results in increased expression of AVPR1A mRNA |
CTD |
PMID:29397400 |
|
NCBI chr12:63,142,759...63,151,201
Ensembl chr12:63,142,759...63,151,201
|
|
G |
AXL |
AXL receptor tyrosine kinase |
increases expression |
EXP |
Etoposide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:41,219,223...41,261,766
Ensembl chr19:41,219,223...41,261,766
|
|
G |
BACE2 |
beta-secretase 2 |
affects response to substance |
EXP |
BACE2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr21:41,168,160...41,282,530
Ensembl chr21:41,167,801...41,282,530
|
|
G |
BAG2 |
BAG cochaperone 2 |
affects response to substance |
EXP |
BAG2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:57,172,326...57,189,833
Ensembl chr 6:57,172,326...57,189,833
|
|
G |
BAK1 |
BCL2 antagonist/killer 1 |
increases activity increases response to substance affects response to substance multiple interactions affects expression |
EXP ISO |
Etoposide results in increased activity of BAK1 protein BAK1 protein results in increased susceptibility to Etoposide BAK1 protein affects the susceptibility to Etoposide nimesulide inhibits the reaction [Etoposide results in increased activity of BAK1 protein] Etoposide affects the expression of BAK1 protein |
CTD |
PMID:15215046 PMID:16077961 PMID:17688235 PMID:21745461 |
|
NCBI chr 6:33,572,552...33,580,276
Ensembl chr 6:33,572,547...33,580,293
|
|
G |
BAMBI |
BMP and activin membrane bound inhibitor |
affects response to substance |
EXP |
BAMBI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression decreases folding affects response to substance |
EXP ISO |
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [Cisplatin co-treated with Etoposide] affects the localization of BAX protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; Etoposide results in increased activity of and affects the localization of BAX protein; Etoposide results in increased cleavage of and results in increased expression of BAX protein; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; nimesulide inhibits the reaction [Etoposide results in increased activity of and affects the localization of BAX protein] Etoposide results in increased expression of BAX mRNA; Etoposide results in increased expression of BAX protein BAX protein affects the susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:10620629 PMID:15131059 PMID:16077961 PMID:16120219 PMID:18676776 PMID:21527772 PMID:21745461 PMID:21880625 PMID:29397400 PMID:33148531 More...
|
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBC3 |
BCL2 binding component 3 |
increases expression multiple interactions affects response to substance |
EXP ISO |
Etoposide results in increased expression of BBC3 mRNA; Etoposide results in increased expression of BBC3 protein entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of BBC3 protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of BBC3 protein] BBC3 protein affects the susceptibility to Etoposide |
CTD |
PMID:20477944 PMID:21801448 PMID:25699604 PMID:37956312 |
|
NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of BCL2 mRNA; Etoposide results in decreased expression of BCL2 protein [G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 protein] |
CTD |
PMID:8840993 PMID:9815696 PMID:12063570 PMID:15917659 PMID:16571667 PMID:19408126 PMID:33148531 More...
|
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions affects expression decreases response to substance |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein] Etoposide affects the expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:8840993 PMID:10620629 PMID:11468182 PMID:15215046 PMID:15917659 PMID:19047049 More...
|
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BCL2L2 |
BCL2 like 2 |
decreases response to substance |
EXP |
BCL2L2 results in decreased susceptibility to Etoposide |
CTD |
PMID:14973057 |
|
NCBI chr14:23,306,833...23,311,751
Ensembl chr14:23,298,790...23,311,751
|
|
G |
BCL6B |
BCL6B transcription repressor |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of BCL6B mRNA |
CTD |
PMID:29733421 |
|
NCBI chr17:7,023,050...7,029,644
Ensembl chr17:7,023,050...7,030,290
|
|
G |
BDNF |
brain derived neurotrophic factor |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of BDNF mRNA HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BID |
BH3 interacting domain death agonist |
multiple interactions increases expression increases cleavage |
EXP |
CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Estradiol inhibits the reaction [Etoposide results in increased expression of BID mRNA] |
CTD |
PMID:19426747 PMID:21801448 |
|
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
|
|
G |
BIK |
BCL2 interacting killer |
increases response to substance |
EXP |
BIK protein results in increased susceptibility to Etoposide |
CTD |
PMID:16007125 |
|
NCBI chr22:43,110,750...43,129,712
Ensembl chr22:43,110,750...43,129,712
|
|
G |
BIN1 |
bridging integrator 1 |
increases response to substance |
EXP |
BIN1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21447800 |
|
NCBI chr 2:127,048,023...127,107,154
Ensembl chr 2:127,048,027...127,107,288
|
|
G |
BIN3 |
bridging integrator 3 |
affects response to substance |
EXP |
BIN3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:22,620,418...22,669,121
Ensembl chr 8:22,620,418...22,669,148
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
affects response to substance decreases response to substance increases expression |
EXP |
BIRC2 protein affects the susceptibility to Etoposide BIRC2 protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of BIRC2 mRNA |
CTD |
PMID:10815900 PMID:14970392 PMID:15050749 PMID:16217747 |
|
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
BIRC3 |
baculoviral IAP repeat containing 3 |
decreases response to substance decreases expression multiple interactions |
EXP |
BIRC3 protein results in decreased susceptibility to Etoposide Etoposide results in decreased expression of BIRC3 mRNA [Etoposide co-treated with KN 62] results in decreased expression of BIRC3 protein |
CTD |
PMID:14666661 PMID:15050749 PMID:16120219 |
|
NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
multiple interactions decreases response to substance increases expression |
EXP |
[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; BIRC5 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Estradiol inhibits the reaction [Etoposide results in increased expression of BIRC5 mRNA] BIRC5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15917659 PMID:16322251 PMID:16364925 PMID:16382892 PMID:19211844 PMID:19426747 More...
|
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BIRC7 |
baculoviral IAP repeat containing 7 |
decreases response to substance |
EXP |
BIRC7 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17437058 |
|
NCBI chr20:63,235,905...63,240,495
Ensembl chr20:63,235,883...63,240,495
|
|
G |
BLM |
BLM RecQ like helicase |
decreases expression |
EXP |
Etoposide results in decreased expression of BLM mRNA |
CTD |
PMID:24211769 |
|
NCBI chr15:90,717,346...90,816,166
Ensembl chr15:90,717,346...90,816,166
|
|
G |
BMP6 |
bone morphogenetic protein 6 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728
|
|
G |
BRCA1 |
BRCA1 DNA repair associated |
multiple interactions increases expression decreases expression |
EXP |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein]; pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of BRCA1 protein] Etoposide results in increased expression of BRCA1 protein Etoposide results in decreased expression of BRCA1 mRNA |
CTD |
PMID:15607317 PMID:16417649 PMID:26259609 |
|
NCBI chr17:43,044,295...43,170,327
Ensembl chr17:43,044,295...43,170,245
|
|
G |
BSCL2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Etoposide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 PMID:25270620 |
|
NCBI chr11:62,690,262...62,709,537
Ensembl chr11:62,689,289...62,709,845
|
|
G |
BTG2 |
BTG anti-proliferation factor 2 |
multiple interactions increases expression |
ISO EXP |
TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein] Etoposide results in increased expression of BTG2 mRNA; Etoposide results in increased expression of BTG2 protein |
CTD |
PMID:21382384 PMID:22003191 PMID:24211769 PMID:27358234 |
|
NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602
|
|
G |
BTG3 |
BTG anti-proliferation factor 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of BTG3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr21:17,593,653...17,612,901
Ensembl chr21:17,593,653...17,612,945
|
|
G |
BUB1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
EXP |
Etoposide results in decreased expression of BUB1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 2:110,637,528...110,678,063
Ensembl chr 2:110,637,528...110,678,063
|
|
G |
BUB1B |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
EXP |
Etoposide results in decreased expression of BUB1B mRNA |
CTD |
PMID:16120219 |
|
NCBI chr15:40,161,069...40,221,123
Ensembl chr15:40,161,023...40,221,123
|
|
G |
C1QBP |
complement C1q binding protein |
decreases response to substance |
EXP |
C1QBP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:25354864 |
|
NCBI chr17:5,432,777...5,439,155
Ensembl chr17:5,432,777...5,448,830
|
|
G |
C4orf19 |
chromosome 4 open reading frame 19 |
affects response to substance |
EXP |
C4ORF19 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:37,453,255...37,593,510
Ensembl chr 4:37,453,925...37,623,495
|
|
G |
C5orf22 |
chromosome 5 open reading frame 22 |
affects response to substance |
EXP |
C5ORF22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:31,532,301...31,555,053
Ensembl chr 5:31,532,287...31,555,053
|
|
G |
CAB39 |
calcium binding protein 39 |
decreases expression |
EXP |
Etoposide results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:230,712,842...230,821,075
Ensembl chr 2:230,712,842...230,821,075
|
|
G |
CADPS2 |
calcium dependent secretion activator 2 |
affects response to substance |
EXP |
CADPS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:122,318,411...122,886,460
Ensembl chr 7:122,318,411...122,886,759
|
|
G |
CALCA |
calcitonin related polypeptide alpha |
multiple interactions decreases response to substance |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:16222118 |
|
NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354
|
|
G |
CALM1 |
calmodulin 1 |
increases expression |
EXP |
Etoposide results in increased expression of CALM1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:90,396,502...90,408,268
Ensembl chr14:90,396,502...90,408,268
|
|
G |
CARD10 |
caspase recruitment domain family member 10 |
multiple interactions increases expression |
EXP |
Estradiol inhibits the reaction [Etoposide results in increased expression of CARD10 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr22:37,490,362...37,519,415
Ensembl chr22:37,490,362...37,519,542
|
|
G |
CASP2 |
caspase 2 |
increases expression increases splicing |
EXP |
Etoposide results in increased expression of CASP2 mRNA alternative form Etoposide results in increased splicing of CASP2 mRNA |
CTD |
PMID:14757846 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
affects expression increases cleavage multiple interactions increases activity increases expression |
EXP ISO |
Etoposide affects the expression of CASP3 protein Etoposide results in increased cleavage of CASP3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [Etoposide co-treated with Mifepristone] results in increased activity of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; Dehydroascorbic Acid promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Etoposide promotes the reaction [Gold results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Silver results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased expression of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased cleavage of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein] Etoposide results in increased expression of CASP3 protein; Etoposide results in increased expression of CASP3 protein modified form [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of CASP3 protein 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Etoposide results in increased activity of CASP3 protein] |
CTD |
PMID:8840993 PMID:10759716 PMID:12871656 PMID:15215046 PMID:15924153 PMID:16014620 PMID:16192531 PMID:16364925 PMID:16545138 PMID:16844113 PMID:16951922 PMID:17516866 PMID:17935137 PMID:18056177 PMID:18649362 PMID:19047049 PMID:19408126 PMID:19662097 PMID:19760634 PMID:20299546 PMID:20573984 PMID:21617849 PMID:21745461 PMID:21745629 PMID:21801448 PMID:21880625 PMID:22275372 PMID:22302033 PMID:23144690 PMID:25447644 PMID:26259609 PMID:29027213 PMID:30217652 PMID:30890322 PMID:33148531 PMID:35065218 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions increases activity |
EXP ISO |
[STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein] 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein] |
CTD |
PMID:18056177 PMID:18649362 PMID:20299546 PMID:21801448 PMID:22275372 PMID:22302033 PMID:26259609 More...
|
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases response to substance increases cleavage increases activity decreases response to substance |
EXP |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP8 protein; Etoposide results in increased expression of and results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP8 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein] CASP8 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15475000 PMID:21745461 PMID:21801448 PMID:22010212 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases cleavage increases activity affects expression |
EXP |
[CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Etoposide results in increased cleavage of and results in increased activity of CASP9 protein; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] Etoposide affects the expression of CASP9 protein |
CTD |
PMID:12925536 PMID:15215046 PMID:16364925 PMID:16799960 PMID:17935137 PMID:18056177 PMID:18676776 PMID:21324178 PMID:21745461 PMID:21801448 More...
|
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CASQ2 |
calsequestrin 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of CASQ2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:115,700,021...115,768,714
Ensembl chr 1:115,700,021...115,768,884
|
|
G |
CAST |
calpastatin |
multiple interactions |
EXP |
CAST inhibits the reaction [Etoposide results in increased degradation of AR protein] |
CTD |
PMID:18726991 |
|
NCBI chr 5:95,961,429...96,774,683
Ensembl chr 5:96,525,267...96,779,595 Ensembl chr 5:96,525,267...96,779,595
|
|
G |
CAT |
catalase |
increases response to substance increases activity multiple interactions |
EXP ISO |
CAT results in increased susceptibility to Etoposide Etoposide results in increased activity of CAT protein EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein] |
CTD |
PMID:21689642 PMID:25451571 PMID:29069929 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCDC51 |
coiled-coil domain containing 51 |
decreases expression |
EXP |
Etoposide results in decreased expression of CCDC51 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 3:48,432,173...48,446,652
Ensembl chr 3:48,432,164...48,440,456
|
|
G |
CCDC6 |
coiled-coil domain containing 6 |
increases response to substance decreases response to substance |
EXP |
CCDC6 results in increased susceptibility to Etoposide CCDC6 results in decreased susceptibility to Etoposide |
CTD |
PMID:22363533 PMID:22655027 |
|
NCBI chr10:59,788,747...59,906,556
Ensembl chr10:59,788,747...59,906,556
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
increases expression |
EXP |
Etoposide results in increased expression of CCL3 protein |
CTD |
PMID:10540334 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCN2 |
cellular communication network factor 2 |
increases expression |
EXP |
Etoposide results in increased expression of CCN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCNA2 |
cyclin A2 |
multiple interactions decreases expression |
EXP |
Etoposide affects the expression of and affects the localization of CCNA2 protein Etoposide results in decreased expression of CCNA2 mRNA; Etoposide results in decreased expression of CCNA2 protein |
CTD |
PMID:16120219 PMID:17390037 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCNB1 |
cyclin B1 |
decreases expression |
EXP |
Etoposide results in decreased expression of CCNB1 mRNA; Etoposide results in decreased expression of CCNB1 protein |
CTD |
PMID:16120219 |
|
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
|
|
G |
CCND1 |
cyclin D1 |
increases expression |
EXP |
Etoposide results in increased expression of CCND1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNG1 |
cyclin G1 |
increases expression |
ISO |
Etoposide results in increased expression of CCNG1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:163,437,571...163,457,640
Ensembl chr 5:163,437,569...163,446,151
|
|
G |
CCNG2 |
cyclin G2 |
increases expression |
EXP |
Etoposide results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 |
|
NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388
|
|
G |
CCS |
copper chaperone for superoxide dismutase |
increases expression |
EXP |
Etoposide results in increased expression of CCS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:66,593,185...66,606,019
Ensembl chr11:66,593,153...66,606,019
|
|
G |
CCT8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of CCT8 protein |
CTD |
PMID:29733421 |
|
NCBI chr21:29,056,326...29,073,648
Ensembl chr21:29,055,805...29,073,797
|
|
G |
CD274 |
CD274 molecule |
increases expression |
EXP |
Etoposide results in increased expression of CD274 protein |
CTD |
PMID:17920123 |
|
NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566
|
|
G |
CD40LG |
CD40 ligand |
multiple interactions decreases response to substance |
EXP |
CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] CD40LG protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16545138 |
|
NCBI chr X:136,648,158...136,660,390
Ensembl chr X:136,648,158...136,660,390
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
affects response to substance multiple interactions |
EXP |
CD44 protein affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:15215046 PMID:19047049 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CD55 |
CD55 molecule (Cromer blood group) |
affects response to substance |
EXP |
CD55 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:207,321,678...207,360,966
Ensembl chr 1:207,321,519...207,386,804
|
|
G |
CD59 |
CD59 molecule (CD59 blood group) |
multiple interactions |
EXP |
[Cisplatin co-treated with Etoposide] results in decreased expression of CD59 protein |
CTD |
PMID:21826740 |
|
NCBI chr11:33,703,010...33,736,479
Ensembl chr11:33,703,010...33,736,479
|
|
G |
CDC25A |
cell division cycle 25A |
decreases expression |
EXP |
Etoposide results in decreased expression of CDC25A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 3:48,157,146...48,188,417
Ensembl chr 3:48,157,146...48,188,417
|
|
G |
CDC25C |
cell division cycle 25C |
decreases expression |
EXP |
Etoposide results in decreased expression of CDC25C mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 5:138,285,265...138,338,355
Ensembl chr 5:138,285,269...138,338,355
|
|
G |
CDC42BPG |
CDC42 binding protein kinase gamma |
increases expression |
ISO |
Etoposide results in increased expression of CDC42BPG mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:64,823,052...64,844,653
Ensembl chr11:64,823,052...64,844,653
|
|
G |
CDC45 |
cell division cycle 45 |
decreases expression |
EXP |
Etoposide results in decreased expression of CDC45 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr22:19,479,466...19,520,612
Ensembl chr22:19,479,457...19,520,612
|
|
G |
CDC6 |
cell division cycle 6 |
decreases expression |
EXP |
Etoposide results in decreased expression of CDC6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr17:40,287,879...40,304,657
Ensembl chr17:40,287,879...40,304,657
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
multiple interactions increases expression affects response to substance |
EXP |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] CDK2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 PMID:16417649 PMID:20149834 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP ISO |
[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of CDKN1A protein]; KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]; Resveratrol inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of CDKN1A protein] Etoposide results in increased expression of CDKN1A mRNA; Etoposide results in increased expression of CDKN1A protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:14601052 PMID:16120219 PMID:16882877 PMID:17516866 PMID:21212465 PMID:21526190 PMID:21527772 PMID:21617849 PMID:21801448 PMID:21880625 PMID:23690541 PMID:24067374 PMID:24211769 PMID:25078064 PMID:25699604 PMID:25914138 PMID:26055805 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 More...
|
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of CDKN1B protein wortmannin promotes the reaction [Etoposide results in increased expression of CDKN1B protein] |
CTD |
PMID:17935137 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDKN2A |
cyclin dependent kinase inhibitor 2A |
multiple interactions increases expression |
ISO |
[CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein] Etoposide results in increased expression of CDKN2A mRNA cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA] |
CTD |
PMID:21526190 PMID:23690541 |
|
NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301
|
|
G |
CDKN3 |
cyclin dependent kinase inhibitor 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218
|
|
G |
CEACAM1 |
CEA cell adhesion molecule 1 |
increases expression |
EXP |
Etoposide results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr19:42,507,306...42,528,481
Ensembl chr19:42,507,304...42,561,234
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
decreases expression increases degradation |
EXP |
Etoposide results in decreased expression of CEBPA mRNA; Etoposide results in decreased expression of CEBPA protein Etoposide results in increased degradation of CEBPA protein |
CTD |
PMID:19662097 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CEBPZ |
CCAAT enhancer binding protein zeta |
decreases expression |
EXP |
Etoposide results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:37,201,612...37,231,596
Ensembl chr 2:37,201,612...37,231,596
|
|
G |
CEL |
carboxyl ester lipase |
increases expression |
EXP |
Etoposide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,981...133,071,861
|
|
G |
CENPF |
centromere protein F |
decreases expression |
EXP |
Etoposide results in decreased expression of CENPF mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:214,603,195...214,664,571
Ensembl chr 1:214,603,185...214,664,574
|
|
G |
CERCAM |
cerebral endothelial cell adhesion molecule |
increases expression |
ISO |
Etoposide results in increased expression of CERCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:128,419,160...128,437,351
Ensembl chr 9:128,411,751...128,437,351
|
|
G |
CES1 |
carboxylesterase 1 |
increases expression |
ISO |
Etoposide results in increased expression of CES1D mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CETP |
cholesteryl ester transfer protein |
multiple interactions increases expression |
EXP |
[Tretinoin co-treated with Etoposide] results in increased expression of CETP mRNA; Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA]; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]]; Tretinoin promotes the reaction [Etoposide results in increased expression of CETP protein] Etoposide results in increased expression of CETP mRNA; Etoposide results in increased expression of CETP protein |
CTD |
PMID:25914138 |
|
NCBI chr16:56,961,950...56,983,845
Ensembl chr16:56,961,923...56,983,845
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
increases expression |
EXP |
Etoposide results in increased expression of CFLAR protein |
CTD |
PMID:14601052 |
|
NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
|
|
G |
CGREF1 |
cell growth regulator with EF-hand domain 1 |
increases expression |
ISO |
Etoposide results in increased expression of CGREF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:27,099,353...27,119,128
Ensembl chr 2:27,098,889...27,119,128
|
|
G |
CHAC1 |
ChaC glutathione specific gamma-glutamylcyclotransferase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:40,953,471...40,956,512
Ensembl chr15:40,952,962...40,956,512
|
|
G |
CHAF1A |
chromatin assembly factor 1 subunit A |
decreases expression |
EXP |
Etoposide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr19:4,402,640...4,450,830
Ensembl chr19:4,402,640...4,445,018
|
|
G |
CHEK1 |
checkpoint kinase 1 |
affects response to substance multiple interactions |
EXP |
CHEK1 protein affects the susceptibility to Etoposide TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide] |
CTD |
PMID:18698031 |
|
NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255
|
|
G |
CHEK2 |
checkpoint kinase 2 |
increases phosphorylation multiple interactions |
ISO EXP |
Etoposide results in increased phosphorylation of CHEK2 protein 4-fluoro-2-(4-(4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:21186793 PMID:22242153 PMID:26259609 |
|
NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422
|
|
G |
CHI3L1 |
chitinase 3 like 1 |
decreases response to substance |
EXP |
CHI3L1 results in decreased susceptibility to Etoposide |
CTD |
PMID:20506295 |
|
NCBI chr 1:203,178,931...203,186,704
Ensembl chr 1:203,178,931...203,186,704
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression |
EXP |
Etoposide results in decreased expression of CHUK protein |
CTD |
PMID:30177839 |
|
NCBI chr10:100,186,319...100,229,596
Ensembl chr10:100,188,300...100,229,596
|
|
G |
CIAPIN1 |
cytokine induced apoptosis inhibitor 1 |
decreases response to substance |
EXP |
CIAPIN1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18389626 |
|
NCBI chr16:57,428,187...57,447,385
Ensembl chr16:57,428,187...57,447,420
|
|
G |
CKM |
creatine kinase, M-type |
decreases expression |
EXP |
Etoposide results in decreased expression of CKM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875
|
|
G |
CKMT1B |
creatine kinase, mitochondrial 1B |
affects response to substance |
EXP |
CKMT1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:43,592,857...43,599,406
Ensembl chr15:43,593,054...43,604,901 Ensembl chr15:43,593,054...43,604,901
|
|
G |
COA7 |
cytochrome c oxidase assembly factor 7 |
decreases expression |
EXP |
Etoposide results in decreased expression of COA7 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:52,684,449...52,698,347
Ensembl chr 1:52,684,449...52,698,347
|
|
G |
COBL |
cordon-bleu WH2 repeat protein |
decreases expression |
ISO |
Etoposide results in decreased expression of COBL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:51,016,212...51,316,809
Ensembl chr 7:51,016,212...51,316,818
|
|
G |
COL15A1 |
collagen type XV alpha 1 chain |
affects response to substance |
EXP |
COL15A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:98,943,907...99,070,787
Ensembl chr 9:98,943,179...99,070,787
|
|
G |
COL4A1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Etoposide results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:110,148,963...110,307,157
Ensembl chr13:110,148,963...110,307,157
|
|
G |
COL9A3 |
collagen type IX alpha 3 chain |
affects response to substance |
EXP |
COL9A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:62,816,213...62,841,159
Ensembl chr20:62,816,244...62,841,159
|
|
G |
COX6A2 |
cytochrome c oxidase subunit 6A2 |
decreases expression |
EXP |
Etoposide results in decreased expression of COX6A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:31,427,731...31,428,360
Ensembl chr16:31,427,731...31,428,360
|
|
G |
CPS1 |
carbamoyl-phosphate synthase 1 |
affects response to substance |
EXP |
CPS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:210,477,685...210,679,107
Ensembl chr 2:210,477,682...210,679,107
|
|
G |
CPT2 |
carnitine palmitoyltransferase 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of CPT2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197
|
|
G |
CRABP2 |
cellular retinoic acid binding protein 2 |
increases expression |
EXP |
Etoposide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:156,699,606...156,705,784
Ensembl chr 1:156,699,606...156,705,816
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO EXP |
Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein; HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20573984 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CREM |
cAMP responsive element modulator |
affects response to substance |
EXP |
CREM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:35,126,846...35,212,958
Ensembl chr10:35,126,791...35,212,958
|
|
G |
CRIP2 |
cysteine rich protein 2 |
increases expression |
ISO |
Etoposide results in increased expression of CRIP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:105,472,945...105,480,170
Ensembl chr14:105,472,962...105,480,162
|
|
G |
CSGALNACT1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
affects response to substance |
EXP |
CSGALNACT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:19,404,161...19,757,908
Ensembl chr 8:19,404,161...19,758,029
|
|
G |
CST1 |
cystatin SN |
affects response to substance |
EXP |
CST1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:23,747,562...23,750,935
Ensembl chr20:23,747,562...23,751,268
|
|
G |
CTH |
cystathionine gamma-lyase |
affects response to substance |
EXP |
CTH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:70,411,268...70,439,851
Ensembl chr 1:70,411,218...70,439,851
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CXCL12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
EXP |
Etoposide results in decreased expression of CXCL12 mRNA; Etoposide results in decreased expression of CXCL12 protein |
CTD |
PMID:22363485 |
|
NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of CXCL8 mRNA; Etoposide results in increased expression of CXCL8 protein SB 203580 inhibits the reaction [Etoposide results in increased expression of CXCL8 protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Etoposide results in increased expression of CXCL8 protein] |
CTD |
PMID:10540334 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization |
EXP |
Etoposide affects the localization of CYCS protein |
CTD |
PMID:10759716 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of CYP1A1 mRNA; Etoposide results in increased expression of CYP1A1 protein Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein] |
CTD |
PMID:29471073 PMID:31542801 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases expression |
EXP |
Etoposide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:31542801 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP26A1 |
cytochrome P450 family 26 subfamily A member 1 |
decreases response to substance |
EXP |
CYP26A1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15703382 |
|
NCBI chr10:93,073,475...93,077,885
Ensembl chr10:93,073,475...93,077,885
|
|
G |
CYP27B1 |
cytochrome P450 family 27 subfamily B member 1 |
increases expression |
EXP |
Etoposide results in increased expression of CYP27B1 mRNA |
CTD |
PMID:17716971 |
|
NCBI chr12:57,762,334...57,767,078
Ensembl chr12:57,762,334...57,768,986
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
increases expression |
ISO |
Etoposide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2S1 |
cytochrome P450 family 2 subfamily S member 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CYP2S1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:41,193,219...41,207,539
Ensembl chr19:41,193,210...41,207,539
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions increases expression decreases methylation affects response to substance |
EXP |
[Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide] Etoposide results in increased expression of CYP3A4 mRNA CYP3A4 gene polymorphism affects the susceptibility to Etoposide; CYP3A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:8114683 PMID:12969965 PMID:17279585 PMID:25455453 PMID:31542801 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
affects response to substance decreases methylation |
EXP |
CYP3A5 gene polymorphism affects the susceptibility to Etoposide CYP3A5 protein results in decreased methylation of Etoposide |
CTD |
PMID:8114683 PMID:12969965 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYREN |
cell cycle regulator of NHEJ |
affects localization |
EXP |
Etoposide affects the localization of CYREN protein alternative form |
CTD |
PMID:24610814 |
|
NCBI chr 7:135,092,303...135,172,469
Ensembl chr 7:135,092,363...135,170,795
|
|
G |
DAB2 |
DAB adaptor protein 2 |
affects response to substance |
EXP |
DAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:39,371,677...39,424,980
Ensembl chr 5:39,371,675...39,462,300
|
|
G |
DAPK1 |
death associated protein kinase 1 |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of DAPK1 protein; Etoposide results in increased expression of DAPK1 protein modified form DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein] |
CTD |
PMID:30177839 |
|
NCBI chr 9:87,497,228...87,708,634
Ensembl chr 9:87,497,228...87,708,634
|
|
G |
DBF4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
ISO |
Etoposide results in decreased expression of DBF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:87,876,493...87,909,553
Ensembl chr 7:87,876,216...87,909,553
|
|
G |
DBN1 |
drebrin 1 |
affects response to substance |
EXP |
DBN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:177,456,610...177,473,634
Ensembl chr 5:177,456,608...177,474,401
|
|
G |
DCAF4 |
DDB1 and CUL4 associated factor 4 |
increases expression |
ISO |
Etoposide results in increased expression of DCAF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:72,926,464...72,962,098
Ensembl chr14:72,926,377...72,959,703
|
|
G |
DCT |
dopachrome tautomerase |
affects response to substance |
EXP |
DCT protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:94,436,811...94,549,406
Ensembl chr13:94,436,811...94,479,682
|
|
G |
DDIT4 |
DNA damage inducible transcript 4 |
affects response to substance |
EXP |
DDIT4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036
|
|
G |
DDR1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Etoposide results in increased expression of DDR1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:30,880,970...30,900,156
Ensembl chr 6:30,876,421...30,900,156
|
|
G |
DES |
desmin |
decreases expression |
EXP |
Etoposide results in decreased expression of DES mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:219,418,377...219,426,734
Ensembl chr 2:219,418,377...219,426,735
|
|
G |
DKK3 |
dickkopf WNT signaling pathway inhibitor 3 |
affects response to substance |
EXP |
DKK3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:11,963,036...12,009,745
Ensembl chr11:11,956,207...12,009,769
|
|
G |
DMD |
dystrophin |
affects response to substance decreases expression |
EXP |
DMD protein affects the susceptibility to Etoposide Etoposide results in decreased expression of DMD mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr X:31,119,222...33,339,388
Ensembl chr X:31,097,677...33,339,609
|
|
G |
DMRT1 |
doublesex and mab-3 related transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of DMRT1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:841,697...969,090
Ensembl chr 9:841,690...969,090
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
decreases response to substance |
ISO EXP |
DNMT1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286
|
|
G |
DNMT3B |
DNA methyltransferase 3 beta |
decreases response to substance |
EXP |
DNMT3B protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr20:32,762,385...32,809,356
Ensembl chr20:32,762,385...32,809,359
|
|
G |
DPP7 |
dipeptidyl peptidase 7 |
multiple interactions |
EXP |
Etoposide promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] |
CTD |
PMID:16725115 |
|
NCBI chr 9:137,110,546...137,118,306
Ensembl chr 9:137,110,542...137,118,309
|
|
G |
DPYSL2 |
dihydropyrimidinase like 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of DPYSL2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 8:26,514,031...26,658,175
Ensembl chr 8:26,514,031...26,658,178
|
|
G |
DPYSL4 |
dihydropyrimidinase like 4 |
increases expression |
EXP |
Etoposide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr10:132,186,948...132,205,759
Ensembl chr10:132,186,948...132,205,759
|
|
G |
DUSP2 |
dual specificity phosphatase 2 |
affects response to substance |
EXP |
DUSP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:96,143,169...96,145,440
Ensembl chr 2:96,143,169...96,145,440
|
|
G |
DUSP4 |
dual specificity phosphatase 4 |
affects response to substance increases expression |
EXP |
DUSP4 protein affects the susceptibility to Etoposide Etoposide results in increased expression of DUSP4 mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr 8:29,333,064...29,350,684
Ensembl chr 8:29,333,064...29,350,684
|
|
G |
E2F1 |
E2F transcription factor 1 |
multiple interactions |
EXP |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EDNRB |
endothelin receptor type B |
decreases expression |
ISO |
Etoposide results in decreased expression of EDNRB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:77,895,481...77,975,527
Ensembl chr13:77,895,481...77,975,529
|
|
G |
EFS |
embryonal Fyn-associated substrate |
increases expression |
ISO |
Etoposide results in increased expression of EFS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:23,356,406...23,365,172
Ensembl chr14:23,356,403...23,365,752
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide |
CTD |
PMID:16969495 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFL8 |
EGF like domain multiple 8 |
affects response to substance |
EXP |
EGFL8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:32,164,595...32,168,281
Ensembl chr 6:32,164,595...32,168,281
|
|
G |
EGFR |
epidermal growth factor receptor |
decreases expression |
EXP |
Etoposide results in decreased expression of EGFR mRNA; Etoposide results in decreased expression of EGFR protein |
CTD |
PMID:15228094 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EI24 |
EI24 autophagy associated transmembrane protein |
increases expression |
EXP |
Etoposide results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:125,569,477...125,584,684
Ensembl chr11:125,569,280...125,584,684
|
|
G |
EIF2S2 |
eukaryotic translation initiation factor 2 subunit beta |
decreases expression |
ISO |
Etoposide results in decreased expression of EIF2S2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:34,088,309...34,112,243
Ensembl chr20:34,088,309...34,112,243
|
|
G |
EIF3A |
eukaryotic translation initiation factor 3 subunit A |
increases response to substance |
EXP ISO |
EIF3A results in increased susceptibility to Etoposide |
CTD |
PMID:21610145 |
|
NCBI chr10:119,033,670...119,080,817
Ensembl chr10:119,033,670...119,080,817
|
|
G |
EMP1 |
epithelial membrane protein 1 |
increases expression |
EXP |
Etoposide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr12:13,196,726...13,219,941
Ensembl chr12:13,196,723...13,219,941
|
|
G |
EMP2 |
epithelial membrane protein 2 |
affects response to substance |
EXP |
EMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:10,528,422...10,580,598
Ensembl chr16:10,528,422...10,580,632
|
|
G |
EMP3 |
epithelial membrane protein 3 (MAM blood group) |
increases expression |
EXP |
Etoposide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:48,325,552...48,330,553
Ensembl chr19:48,321,509...48,330,553
|
|
G |
EN2 |
engrailed homeobox 2 |
affects response to substance |
EXP |
EN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:155,458,129...155,464,831
Ensembl chr 7:155,458,129...155,464,831
|
|
G |
ENO1 |
enolase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ENO1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190
|
|
G |
ENTPD2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ENTPD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:137,048,107...137,054,061
Ensembl chr 9:137,048,107...137,054,061
|
|
G |
EP300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077
|
|
G |
EPB41L3 |
erythrocyte membrane protein band 4.1 like 3 |
affects response to substance |
EXP |
EPB41L3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:5,392,386...5,630,663
Ensembl chr18:5,392,381...5,630,700
|
|
G |
EPHX1 |
epoxide hydrolase 1 |
increases expression |
ISO |
Etoposide results in increased expression of EPHX1 mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
|
|
G |
EPM2AIP1 |
EPM2A interacting protein 1 |
increases expression |
EXP |
Etoposide results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 3:36,985,043...36,993,131
Ensembl chr 3:36,985,043...36,993,131
|
|
G |
EPO |
erythropoietin |
multiple interactions |
EXP |
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]; EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide] |
CTD |
PMID:18403296 PMID:29069929 |
|
NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700
|
|
G |
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression decreases response to substance affects response to substance |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] Etoposide results in decreased expression of ERBB2 mRNA ERBB2 protein results in decreased susceptibility to Etoposide; ERBB2 results in decreased susceptibility to Etoposide ERBB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:10327070 PMID:15228094 PMID:21712253 PMID:25866362 |
|
NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426
|
|
G |
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
affects response to substance decreases expression |
EXP |
ERBB3 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 PMID:16217747 PMID:29397400 |
|
NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505
|
|
G |
ERBB4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
EXP |
Etoposide results in decreased expression of ERBB4 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841
|
|
G |
EREG |
epiregulin |
increases expression |
EXP |
Etoposide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749
|
|
G |
ERVFRD-1 |
endogenous retrovirus group FRD member 1, envelope |
affects response to substance |
EXP |
ERVFRD-1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:11,102,489...11,111,725
Ensembl chr 6:11,102,489...11,111,725
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
increases response to substance multiple interactions |
EXP |
ESR2 protein results in increased susceptibility to Etoposide TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:20623183 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
ESRP1 |
epithelial splicing regulatory protein 1 |
affects response to substance |
EXP |
ESRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:94,641,174...94,707,466
Ensembl chr 8:94,641,074...94,707,466
|
|
G |
ESRRA |
estrogen related receptor alpha |
multiple interactions |
EXP |
Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]; Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr11:64,305,524...64,316,743
Ensembl chr11:64,305,497...64,316,743
|
|
G |
ETS1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions increases expression |
EXP |
DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein] |
CTD |
PMID:30177839 |
|
NCBI chr11:128,458,765...128,587,558
Ensembl chr11:128,458,761...128,587,558
|
|
G |
ETV6 |
ETS variant transcription factor 6 |
increases response to substance increases mutagenesis |
EXP |
ETV6 gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of ETV6 gene |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr12:11,649,674...11,895,377
Ensembl chr12:11,649,674...11,895,377
|
|
G |
EXOC4 |
exocyst complex component 4 |
increases expression |
ISO |
Etoposide results in increased expression of EXOC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:133,253,078...134,100,951
Ensembl chr 7:133,253,073...134,066,589
|
|
G |
F11R |
F11 receptor |
increases expression |
EXP |
Etoposide results in increased expression of F11R mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:160,995,211...161,021,152
Ensembl chr 1:160,995,211...161,021,175
|
|
G |
F2R |
coagulation factor II thrombin receptor |
affects response to substance |
EXP |
F2R protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
EXP |
Etoposide results in increased expression of F3 mRNA |
CTD |
PMID:12542493 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FADS3 |
fatty acid desaturase 3 |
increases expression |
EXP |
Etoposide results in increased expression of FADS3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:61,873,526...61,892,224
Ensembl chr11:61,873,519...61,892,051
|
|
G |
FAM171A1 |
family with sequence similarity 171 member A1 |
affects response to substance |
EXP |
FAM171A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:15,211,643...15,374,554
Ensembl chr10:15,211,643...15,371,289
|
|
G |
FAS |
Fas cell surface death receptor |
multiple interactions increases expression |
EXP ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]; Etoposide results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein] Etoposide results in increased expression of FAS mRNA Etoposide results in increased expression of FAS mRNA; Etoposide results in increased expression of FAS protein |
CTD |
PMID:12513834 PMID:15475000 PMID:16192531 PMID:29397400 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASLG |
Fas ligand |
multiple interactions increases expression increases activity |
EXP ISO |
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] Etoposide results in increased expression of FASL mRNA |
CTD |
PMID:10811113 PMID:12513834 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FASN |
fatty acid synthase |
increases expression |
EXP |
Etoposide results in increased expression of FASN mRNA |
CTD |
PMID:17089011 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FBL |
fibrillarin |
affects localization |
EXP |
Etoposide analog affects the localization of FBL protein |
CTD |
PMID:10942594 |
|
NCBI chr19:39,834,458...39,846,379
Ensembl chr19:39,834,458...39,846,379
|
|
G |
FDFT1 |
farnesyl-diphosphate farnesyltransferase 1 |
affects response to substance |
EXP |
FDFT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395
|
|
G |
FDXR |
ferredoxin reductase |
increases expression |
EXP |
Etoposide results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:74,862,497...74,872,994
Ensembl chr17:74,862,497...74,873,031
|
|
G |
FGF2 |
fibroblast growth factor 2 |
affects response to substance |
EXP |
FGF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FHL1 |
four and a half LIM domains 1 |
affects response to substance |
EXP |
FHL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:136,146,702...136,211,359
Ensembl chr X:136,146,702...136,211,359
|
|
G |
FHL2 |
four and a half LIM domains 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of FHL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:105,357,712...105,438,529
Ensembl chr 2:105,357,712...105,438,513
|
|
G |
FLNC |
filamin C |
increases expression |
EXP |
Etoposide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:128,830,406...128,859,272
Ensembl chr 7:128,830,406...128,859,274
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases response to substance increases expression multiple interactions |
ISO EXP |
FOS protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of FOS [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA; Acetylcysteine inhibits the reaction [Etoposide results in increased expression of FOS] |
CTD |
PMID:10711420 PMID:18314485 PMID:23824011 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSL1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Etoposide results in increased expression of FOSL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
|
|
G |
FOXF2 |
forkhead box F2 |
affects response to substance |
EXP |
FOXF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:1,389,576...1,395,603
Ensembl chr 6:1,389,576...1,395,603
|
|
G |
FOXJ2 |
forkhead box J2 |
decreases expression |
EXP |
Etoposide results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:8,032,716...8,055,517
Ensembl chr12:8,032,716...8,055,517
|
|
G |
FOXO1 |
forkhead box O1 |
increases phosphorylation multiple interactions |
EXP |
Etoposide results in increased phosphorylation of FOXO1 protein wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FOXO3 |
forkhead box O3 |
increases phosphorylation increases response to substance multiple interactions |
EXP |
Etoposide results in increased phosphorylation of FOXO3 protein FOXO3 protein results in increased susceptibility to Etoposide [FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:17935137 PMID:19211844 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
FTH1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO |
HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA] |
CTD |
PMID:20980392 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
FTL |
ferritin light chain |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of FTL mRNA; Etoposide results in increased expression of FTL protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in increased expression of FTL protein]; ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]; Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]; FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]; FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879
|
|
G |
FUT8 |
fucosyltransferase 8 |
affects response to substance |
EXP |
FUT8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:65,356,842...65,744,121
Ensembl chr14:65,410,592...65,744,121
|
|
G |
FYN |
FYN proto-oncogene, Src family tyrosine kinase |
affects response to substance decreases expression |
EXP ISO |
FYN protein affects the susceptibility to Etoposide Etoposide results in decreased expression of FYN mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452
|
|
G |
FZD1 |
frizzled class receptor 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of FZD1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:91,264,433...91,271,326
Ensembl chr 7:91,264,433...91,271,326
|
|
G |
FZD5 |
frizzled class receptor 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of FZD5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:207,762,598...207,769,906
Ensembl chr 2:207,762,598...207,769,906
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
increases response to substance multiple interactions increases expression |
EXP |
GADD45A protein results in increased susceptibility to Etoposide IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein] Etoposide results in increased expression of GADD45A mRNA; Etoposide results in increased expression of GADD45A protein |
CTD |
PMID:19003803 PMID:21527772 PMID:29397400 PMID:30177839 PMID:31542801 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GANAB |
glucosidase II alpha subunit |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of GANAB protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein |
CTD |
PMID:29733421 |
|
NCBI chr11:62,624,829...62,646,613
Ensembl chr11:62,624,826...62,646,726
|
|
G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
Etoposide results in increased expression of GAPDH protein |
CTD |
PMID:29733421 |
|
NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions |
EXP |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
multiple interactions |
EXP |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GDF15 |
growth differentiation factor 15 |
multiple interactions increases expression |
EXP |
Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of GDF15 mRNA; Etoposide results in increased expression of GDF15 protein |
CTD |
PMID:11895857 PMID:16120219 PMID:24211769 PMID:29397400 |
|
NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176
|
|
G |
GJA1 |
gap junction protein alpha 1 |
multiple interactions increases response to substance |
ISO |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Tetradecanoylphorbol Acetate affects the reaction [GJA1 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:23978459 |
|
NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727
|
|
G |
GJA5 |
gap junction protein alpha 5 |
decreases expression |
EXP |
Etoposide results in decreased expression of GJA5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:147,756,199...147,773,351
Ensembl chr 1:147,756,199...147,773,362
|
|
G |
GLS2 |
glutaminase 2 |
increases expression |
EXP |
Etoposide results in increased expression of GLS2 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr12:56,470,952...56,488,161
Ensembl chr12:56,470,944...56,488,414
|
|
G |
GPIHBP1 |
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:143,213,218...143,217,170
Ensembl chr 8:143,213,218...143,217,170
|
|
G |
GPM6B |
glycoprotein M6B |
affects response to substance |
EXP |
GPM6B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:13,770,939...13,938,638
Ensembl chr X:13,770,939...13,938,638
|
|
G |
GPNMB |
glycoprotein nmb |
increases expression |
EXP |
Etoposide results in increased expression of GPNMB mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108
|
|
G |
GPR37 |
G protein-coupled receptor 37 |
affects response to substance |
EXP |
GPR37 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:124,743,885...124,765,792
Ensembl chr 7:124,743,885...124,765,792
|
|
G |
GPSM2 |
G protein signaling modulator 2 |
affects response to substance |
EXP |
GPSM2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:108,876,985...108,934,545
Ensembl chr 1:108,875,350...108,934,545
|
|
G |
GPX1 |
glutathione peroxidase 1 |
increases expression |
EXP |
Etoposide results in increased expression of GPX1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GPX3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Etoposide results in increased expression of GPX3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:151,020,591...151,028,988
Ensembl chr 5:151,020,591...151,028,988
|
|
G |
GRIA3 |
glutamate ionotropic receptor AMPA type subunit 3 |
increases expression |
ISO |
Etoposide results in increased expression of GRIA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:123,184,278...123,490,915
Ensembl chr X:123,184,153...123,490,915
|
|
G |
GRPEL1 |
GrpE like 1, mitochondrial |
decreases expression |
EXP |
Etoposide results in decreased expression of GRPEL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:7,058,895...7,068,064
Ensembl chr 4:7,058,671...7,068,085
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions increases activity |
ISO |
BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein] [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of GSK3B protein |
CTD |
PMID:19408126 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
GSTM1 |
glutathione S-transferase mu 1 |
affects response to substance |
EXP |
GSTM1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
|
|
G |
GSTM4 |
glutathione S-transferase mu 4 |
affects response to substance |
EXP |
GSTM4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:109,656,099...109,667,727
Ensembl chr 1:109,656,099...109,665,496
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions decreases response to substance affects response to substance |
EXP |
Curcumin inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Sulfinpyrazone inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; verlukast inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide] GSTP1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:10900222 PMID:12969965 PMID:15999103 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
GSTT2 |
glutathione S-transferase theta 2 (gene/pseudogene) |
affects response to substance |
EXP |
GSTT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr22:23,980,134...23,983,915
Ensembl chr22:23,980,058...23,983,915
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions decreases response to substance increases expression increases phosphorylation |
EXP ISO |
Celecoxib inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; nimesulide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; pifithrin promotes the reaction [Etoposide results in increased expression of H2AX protein] H2AX protein results in decreased susceptibility to Etoposide 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide results in increased expression of H2AX protein]; RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]; TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione inhibits the reaction [Etoposide results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Razoxane inhibits the reaction [Etoposide results in increased expression of H2AX protein] Etoposide results in increased expression of H2AX protein; Etoposide results in increased expression of H2AX protein modified form |
CTD |
PMID:17875725 PMID:20643100 PMID:20978201 PMID:21555580 PMID:21745461 PMID:22302033 PMID:25078064 PMID:26259609 PMID:28343997 PMID:32482060 PMID:33823233 PMID:34510228 PMID:35690182 PMID:37451322 More...
|
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HAL |
histidine ammonia-lyase |
decreases expression |
ISO |
Etoposide results in decreased expression of HAL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:95,972,662...95,996,344
Ensembl chr12:95,972,662...95,996,365
|
|
G |
HAMP |
hepcidin antimicrobial peptide |
decreases expression multiple interactions |
ISO EXP |
Etoposide results in decreased expression of HAMP mRNA Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25270620 PMID:25633564 |
|
NCBI chr19:35,282,528...35,285,143
Ensembl chr19:35,280,716...35,285,143
|
|
G |
HBEGF |
heparin binding EGF like growth factor |
increases expression |
EXP |
Etoposide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603
|
|
G |
HBP1 |
HMG-box transcription factor 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of HBP1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:107,169,003...107,202,522
Ensembl chr 7:107,168,961...107,202,522
|
|
G |
HDAC4 |
histone deacetylase 4 |
affects response to substance |
EXP |
HDAC4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:239,048,168...239,401,649
Ensembl chr 2:239,048,168...239,401,654
|
|
G |
HEPH |
hephaestin |
affects response to substance |
EXP |
HEPH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:66,162,671...66,268,863
Ensembl chr X:66,162,671...66,268,867
|
|
G |
HIC1 |
HIC ZBTB transcriptional repressor 1 |
multiple interactions increases expression |
EXP |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr17:2,055,103...2,063,241
Ensembl chr17:2,054,154...2,063,241
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; HIF1A mutant form inhibits the reaction [Oxygen deficiency results in decreased susceptibility to Etoposide]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:23144690 PMID:33969609 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HIPK2 |
homeodomain interacting protein kinase 2 |
increases activity multiple interactions decreases response to substance |
EXP ISO |
Etoposide results in increased activity of HIPK2 protein HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] HIPK2 results in decreased susceptibility to Etoposide HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 PMID:20980392 |
|
NCBI chr 7:139,561,570...139,777,998
Ensembl chr 7:139,561,570...139,777,998
|
|
G |
HLA-A |
major histocompatibility complex, class I, A |
affects expression |
EXP |
Etoposide affects the expression of HLA-A mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:29,942,532...29,945,870
Ensembl chr 6:29,941,260...29,949,572
|
|
G |
HLA-B |
major histocompatibility complex, class I, B |
affects expression |
EXP |
Etoposide affects the expression of HLA-B mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:31,353,875...31,357,179
Ensembl chr 6:31,353,872...31,367,067
|
|
G |
HLA-E |
major histocompatibility complex, class I, E |
affects expression |
EXP |
Etoposide affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:30,489,509...30,494,194
Ensembl chr 6:30,489,509...30,494,194
|
|
G |
HMCES |
5-hydroxymethylcytosine binding, ES cell specific |
decreases expression |
ISO |
Etoposide results in decreased expression of HMCES mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:129,278,832...129,306,186
Ensembl chr 3:129,278,828...129,306,186
|
|
G |
HMG20B |
high mobility group 20B |
affects response to substance |
EXP |
HMG20B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:3,572,944...3,579,083
Ensembl chr19:3,572,777...3,579,088
|
|
G |
HMGA2 |
high mobility group AT-hook 2 |
affects response to substance |
EXP |
HMGA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:65,824,460...65,966,291
Ensembl chr12:65,824,460...65,966,291
|
|
G |
HMGB1 |
high mobility group box 1 |
decreases response to substance increases secretion |
EXP |
HMGB1 protein results in decreased susceptibility to Etoposide Etoposide results in increased secretion of HMGB1 protein |
CTD |
PMID:27807322 |
|
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
|
|
G |
HNRNPH2 |
heterogeneous nuclear ribonucleoprotein H2 |
decreases expression |
ISO |
Etoposide results in decreased expression of HNRNPH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr X:101,408,222...101,414,133
Ensembl chr X:101,408,222...101,414,133
|
|
G |
HOXA5 |
homeobox A5 |
affects response to substance |
EXP |
HOXA5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:27,141,052...27,143,681
Ensembl chr 7:27,141,052...27,143,681
|
|
G |
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90AA1 protein |
CTD |
PMID:24478030 |
|
NCBI chr14:102,080,742...102,139,749
Ensembl chr14:102,080,742...102,139,699
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90B1 protein |
CTD |
PMID:24478030 |
|
NCBI chr12:103,930,410...103,947,926
Ensembl chr12:103,930,107...103,953,931
|
|
G |
HSPA2 |
heat shock protein family A (Hsp70) member 2 |
affects response to substance |
EXP |
HSPA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:64,535,905...64,543,237
Ensembl chr14:64,535,905...64,546,173
|
|
G |
HSPE1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
Etoposide results in increased expression of HSPE1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 2:197,500,379...197,503,449
Ensembl chr 2:197,500,140...197,503,449
|
|
G |
HTATIP2 |
HIV-1 Tat interactive protein 2 |
affects response to substance increases response to substance multiple interactions |
EXP ISO |
HTATIP2 protein affects the susceptibility to Etoposide HTATIP2 protein results in increased susceptibility to Etoposide HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein] |
CTD |
PMID:16217747 PMID:16799960 |
|
NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782
|
|
G |
HTR4 |
5-hydroxytryptamine receptor 4 |
affects response to substance |
EXP |
HTR4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:148,451,032...148,654,527
Ensembl chr 5:148,446,042...148,677,235
|
|
G |
IER5 |
immediate early response 5 |
increases expression |
EXP |
Etoposide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:181,088,700...181,092,900
Ensembl chr 1:181,088,700...181,092,900
|
|
G |
IFITM1 |
interferon induced transmembrane protein 1 |
affects response to substance |
EXP |
IFITM1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:314,040...315,272
Ensembl chr11:310,041...315,272
|
|
G |
IGDCC4 |
immunoglobulin superfamily DCC subclass member 4 |
increases expression |
ISO |
Etoposide results in increased expression of IGDCC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:65,381,484...65,422,947
Ensembl chr15:65,381,484...65,422,947
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
affects response to substance |
EXP |
IGF1R protein affects the susceptibility to Etoposide |
CTD |
PMID:15499378 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
IGFBP7 |
insulin like growth factor binding protein 7 |
affects response to substance |
EXP |
IGFBP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:57,030,773...57,110,385
Ensembl chr 4:57,030,773...57,110,385
|
|
G |
IGH |
immunoglobulin heavy locus |
increases mutagenesis |
EXP |
Etoposide results in increased mutagenesis of IGH gene |
CTD |
PMID:28624474 |
|
NCBI chr14:105,586,437...106,879,844
|
|
G |
IGSF11 |
immunoglobulin superfamily member 11 |
decreases expression |
ISO |
Etoposide results in decreased expression of IGSF11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:118,900,557...119,146,020
Ensembl chr 3:118,900,557...119,146,068
|
|
G |
IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
affects response to substance multiple interactions decreases expression |
ISO EXP |
IKBKB protein affects the susceptibility to Etoposide DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein] |
CTD |
PMID:20159942 PMID:30177839 |
|
NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460
|
|
G |
IL1B |
interleukin 1 beta |
increases expression |
ISO |
Etoposide results in increased expression of IL1B mRNA |
CTD |
PMID:18523641 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL4 |
interleukin 4 |
decreases response to substance multiple interactions |
EXP |
IL4 protein results in decreased susceptibility to Etoposide [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased expression of IL6 mRNA]; (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased secretion of IL6 protein] Etoposide results in increased expression of IL6 mRNA; Etoposide results in increased expression of IL6 protein |
CTD |
PMID:15135310 PMID:17003255 PMID:18523641 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INKA2 |
inka box actin regulator 2 |
increases expression |
ISO |
Etoposide results in increased expression of INKA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:111,722,064...111,755,797
Ensembl chr 1:111,680,630...111,755,824
|
|
G |
INSIG1 |
insulin induced gene 1 |
affects response to substance |
EXP |
INSIG1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
INTS15 |
integrator complex subunit 15 |
decreases expression |
EXP |
Etoposide results in decreased expression of INTS15 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:6,590,021...6,608,726
Ensembl chr 7:6,590,021...6,608,726
|
|
G |
IREB2 |
iron responsive element binding protein 2 |
multiple interactions decreases expression |
EXP |
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of IREB2 protein] Etoposide results in decreased expression of IREB2 mRNA; Etoposide results in decreased expression of IREB2 protein |
CTD |
PMID:33969609 |
|
NCBI chr15:78,437,431...78,501,453
Ensembl chr15:78,437,431...78,501,453
|
|
G |
IRS2 |
insulin receptor substrate 2 |
affects response to substance |
EXP |
IRS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:109,752,695...109,786,583
Ensembl chr13:109,752,695...109,786,583
|
|
G |
IRX4 |
iroquois homeobox 4 |
decreases expression |
EXP |
Etoposide results in decreased expression of IRX4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 5:1,877,413...1,887,179
Ensembl chr 5:1,877,413...1,887,236
|
|
G |
ISG15 |
ISG15 ubiquitin like modifier |
increases expression |
EXP |
Etoposide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:1,013,497...1,014,540
Ensembl chr 1:1,001,138...1,014,540
|
|
G |
ISG20 |
interferon stimulated exonuclease gene 20 |
affects response to substance |
EXP |
ISG20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:88,635,632...88,656,483
Ensembl chr15:88,635,670...88,656,483
|
|
G |
ISG20L2 |
interferon stimulated exonuclease gene 20 like 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:156,721,891...156,728,766
Ensembl chr 1:156,721,891...156,728,766
|
|
G |
ITGA2B |
integrin subunit alpha 2b |
increases expression |
EXP |
Etoposide results in increased expression of ITGA2B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:44,372,181...44,389,649
Ensembl chr17:44,372,180...44,389,649
|
|
G |
ITGB3 |
integrin subunit beta 3 |
increases response to substance |
EXP |
ITGB3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21332719 |
|
NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743
|
|
G |
ITPR1 |
inositol 1,4,5-trisphosphate receptor type 1 |
affects response to substance |
EXP |
ITPR1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:4,493,348...4,847,506
Ensembl chr 3:4,493,345...4,847,506
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KCNAB2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
affects response to substance |
EXP |
KCNAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:5,992,676...6,101,180
Ensembl chr 1:5,990,927...6,101,193
|
|
G |
KCNE3 |
potassium voltage-gated channel subfamily E regulatory subunit 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of KCNE3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:74,454,841...74,467,549
Ensembl chr11:74,454,841...74,467,729
|
|
G |
KCNN2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of KCNN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 5:114,055,978...114,496,496
Ensembl chr 5:114,055,926...114,496,500
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
decreases response to substance multiple interactions increases response to substance |
EXP |
KEAP1 protein results in decreased susceptibility to Etoposide KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein] KEAP1 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:22684020 PMID:26708503 PMID:27982581 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
KIF1A |
kinesin family member 1A |
increases expression |
EXP |
Etoposide results in increased expression of KIF1A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:240,713,767...240,821,403
Ensembl chr 2:240,713,761...240,824,293
|
|
G |
KIF20A |
kinesin family member 20A |
decreases expression |
EXP |
Etoposide results in decreased expression of KIF20A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:138,179,112...138,187,723
Ensembl chr 5:138,178,719...138,187,723
|
|
G |
KIF23 |
kinesin family member 23 |
decreases expression |
ISO |
Etoposide results in decreased expression of KIF23 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:69,414,349...69,448,427
Ensembl chr15:69,414,246...69,448,427
|
|
G |
KIT |
KIT proto-oncogene, receptor tyrosine kinase |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of KIT protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein |
CTD |
PMID:29733421 |
|
NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,267...54,740,783
|
|
G |
KLF4 |
KLF transcription factor 4 |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of KLF4 mRNA; Etoposide results in increased expression of KLF4 protein FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
|
|
G |
KLF5 |
KLF transcription factor 5 |
increases expression |
EXP |
Etoposide results in increased expression of KLF5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541
|
|
G |
KLF6 |
KLF transcription factor 6 |
decreases expression |
EXP |
Etoposide results in decreased expression of KLF6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
KLHL26 |
kelch like family member 26 |
increases expression |
ISO |
Etoposide results in increased expression of KLHL26 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:18,637,028...18,671,721
Ensembl chr19:18,637,025...18,671,721
|
|
G |
KLK2 |
kallikrein related peptidase 2 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK2 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr19:50,873,439...50,880,567
Ensembl chr19:50,861,568...50,880,567
|
|
G |
KLK3 |
kallikrein related peptidase 3 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764
|
|
G |
KMT2A |
lysine methyltransferase 2A |
increases response to substance increases mutagenesis increases cleavage |
EXP |
KMT2A gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of KMT2A gene Etoposide results in increased cleavage of KMT2A gene |
CTD |
PMID:14712291 PMID:24086652 PMID:28624474 |
|
NCBI chr11:118,436,492...118,526,832
Ensembl chr11:118,436,456...118,526,832
|
|
G |
KRT19 |
keratin 19 |
increases expression |
EXP |
Etoposide results in increased expression of KRT19 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr17:41,523,617...41,528,308
Ensembl chr17:41,523,617...41,528,308
|
|
G |
KRT80 |
keratin 80 |
increases expression |
EXP |
Etoposide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr12:52,168,996...52,192,014
Ensembl chr12:52,168,996...52,192,014
|
|
G |
KYNU |
kynureninase |
affects response to substance |
EXP |
KYNU protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:142,877,664...143,055,833
Ensembl chr 2:142,877,657...143,055,833
|
|
G |
LANCL1 |
LanC like glutathione S-transferase 1 |
affects response to substance |
EXP |
LANCL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:210,431,251...210,477,584
Ensembl chr 2:210,427,131...210,477,652
|
|
G |
LAP3 |
leucine aminopeptidase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of LAP3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:17,577,198...17,607,970
Ensembl chr 4:17,577,198...17,607,972
|
|
G |
LCN2 |
lipocalin 2 |
increases response to substance |
ISO |
LCN2 protein results in increased susceptibility to Etoposide |
CTD |
PMID:19860839 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
LDB3 |
LIM domain binding 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of LDB3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:86,666,788...86,736,072
Ensembl chr10:86,666,785...86,736,072
|
|
G |
LGALS3 |
galectin 3 |
affects response to substance |
EXP |
LGALS3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:55,129,252...55,145,430
Ensembl chr14:55,124,110...55,145,423
|
|
G |
LGALS7 |
galectin 7 |
increases expression |
EXP |
Etoposide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:38,770,968...38,773,517
Ensembl chr19:38,789,200...38,791,754 Ensembl chr19:38,789,200...38,791,754
|
|
G |
LHX1 |
LIM homeobox 1 |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA Etoposide results in decreased expression of LHX1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr17:36,936,785...36,944,612
Ensembl chr17:36,936,785...36,944,612
|
|
G |
LHX2 |
LIM homeobox 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of LHX2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:124,011,768...124,033,301
Ensembl chr 9:124,001,670...124,033,301
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
increases expression |
EXP |
Etoposide results in increased expression of LIF mRNA |
CTD |
PMID:29397400 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
LIMCH1 |
LIM and calponin homology domains 1 |
affects response to substance |
EXP |
LIMCH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:41,359,607...41,700,044
Ensembl chr 4:41,359,607...41,700,044
|
|
G |
LIPA |
lipase A, lysosomal acid type |
affects response to substance |
EXP |
LIPA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:89,213,572...89,251,775
Ensembl chr10:89,213,569...89,414,557
|
|
G |
LRRC47 |
leucine rich repeat containing 47 |
decreases expression |
EXP |
Etoposide results in decreased expression of LRRC47 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:3,778,559...3,796,498
Ensembl chr 1:3,778,559...3,796,498
|
|
G |
LTBR |
lymphotoxin beta receptor |
multiple interactions increases expression |
EXP |
Estradiol inhibits the reaction [Etoposide results in increased expression of LTBR mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr12:6,375,160...6,391,566
Ensembl chr12:6,375,045...6,391,571
|
|
G |
LXN |
latexin |
increases response to substance |
ISO |
LXN protein results in increased susceptibility to Etoposide |
CTD |
PMID:25341047 |
|
NCBI chr 3:158,666,414...158,672,648
Ensembl chr 3:158,645,822...158,672,648
|
|
G |
LY6E |
lymphocyte antigen 6 family member E |
affects response to substance |
EXP |
LY6E protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:143,018,529...143,022,409
Ensembl chr 8:143,017,982...143,023,832
|
|
G |
MACF1 |
microtubule actin crosslinking factor 1 |
affects response to substance |
EXP |
MACF1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:39,084,167...39,487,138
Ensembl chr 1:39,081,316...39,487,177
|
|
G |
MAGEA12 |
MAGE family member A12 |
affects response to substance |
EXP |
MAGEA12 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:152,733,757...152,737,669
Ensembl chr X:152,733,757...152,737,669
|
|
G |
MAGEA6 |
MAGE family member A6 |
affects response to substance |
EXP |
MAGEA6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:152,766,136...152,769,689
Ensembl chr X:152,766,136...152,769,716
|
|
G |
MAGEC1 |
MAGE family member C1 |
affects response to substance |
EXP |
MAGEC1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:141,903,894...141,909,374
Ensembl chr X:141,903,894...141,909,374
|
|
G |
MAN2B1 |
mannosidase alpha class 2B member 1 |
increases expression |
ISO |
Etoposide results in increased expression of MAN2B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:12,646,512...12,666,742
Ensembl chr19:12,646,511...12,666,742
|
|
G |
MAP2K3 |
mitogen-activated protein kinase kinase 3 |
increases expression |
EXP |
Etoposide results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:21,284,711...21,315,240
Ensembl chr17:21,284,672...21,315,232
|
|
G |
MAP3K5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
EXP |
Etoposide results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097
|
|
G |
MAP7 |
microtubule associated protein 7 |
affects response to substance |
EXP |
MAP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:136,342,734...136,550,422
Ensembl chr 6:136,342,281...136,550,819
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK12 |
mitogen-activated protein kinase 12 |
increases activity affects response to substance multiple interactions |
EXP |
Etoposide results in increased activity of MAPK12 protein MAPK12 protein affects the susceptibility to Etoposide [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:21878638 |
|
NCBI chr22:50,252,901...50,261,683
Ensembl chr22:50,245,450...50,261,716
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPKAPK2 |
MAPK activated protein kinase 2 |
multiple interactions increases phosphorylation |
ISO |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased phosphorylation of MAPKAPK2 protein] |
CTD |
PMID:17003255 |
|
NCBI chr 1:206,684,905...206,734,281
Ensembl chr 1:206,684,905...206,734,281
|
|
G |
MATN2 |
matrilin 2 |
affects response to substance |
EXP |
MATN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:97,869,064...98,036,724
Ensembl chr 8:97,868,840...98,036,724
|
|
G |
MBP |
myelin basic protein |
affects response to substance |
EXP |
MBP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683
|
|
G |
MCAM |
melanoma cell adhesion molecule |
increases expression |
ISO |
Etoposide results in increased expression of MCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:119,308,529...119,317,130
Ensembl chr11:119,308,529...119,321,521
|
|
G |
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
EXP |
wortmannin promotes the reaction [Etoposide results in decreased expression of MCL1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738
|
|
G |
MCM10 |
minichromosome maintenance 10 replication initiation factor |
decreases expression |
EXP |
Etoposide results in decreased expression of MCM10 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr10:13,161,558...13,211,110
Ensembl chr10:13,161,558...13,211,110
|
|
G |
MCM2 |
minichromosome maintenance complex component 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of MCM2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:127,598,411...127,622,436
Ensembl chr 3:127,598,410...127,622,436
|
|
G |
MCM6 |
minichromosome maintenance complex component 6 |
decreases expression |
EXP |
Etoposide results in decreased expression of MCM6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 2:135,839,626...135,876,443
Ensembl chr 2:135,839,626...135,876,443
|
|
G |
MCM7 |
minichromosome maintenance complex component 7 |
decreases expression |
EXP |
Etoposide results in decreased expression of MCM7 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,233...100,101,940
|
|
G |
MCM8 |
minichromosome maintenance 8 homologous recombination repair factor |
decreases expression |
EXP |
Etoposide results in decreased expression of MCM8 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr20:5,950,652...5,998,977
Ensembl chr20:5,950,652...5,998,977
|
|
G |
MDFIC |
MyoD family inhibitor domain containing |
affects response to substance |
EXP |
MDFIC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:114,922,094...115,019,917
Ensembl chr 7:114,922,094...115,019,917
|
|
G |
MDH2 |
malate dehydrogenase 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of MDH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:76,048,106...76,067,508
Ensembl chr 7:76,048,051...76,067,508
|
|
G |
MDM2 |
MDM2 proto-oncogene |
multiple interactions decreases expression increases phosphorylation increases expression decreases response to substance |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein] Etoposide results in decreased expression of MDM2 protein Etoposide results in increased expression of MDM2 mRNA; Etoposide results in increased expression of MDM2 protein; Etoposide results in increased expression of MDM2 protein modified form Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein] MDM2 promoter SNP results in decreased susceptibility to Etoposide |
CTD |
PMID:15459018 PMID:16120219 PMID:17575151 PMID:17935137 PMID:18096571 PMID:25078064 PMID:25744307 PMID:26259609 PMID:30177839 PMID:31542801 More...
|
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
ME2 |
malic enzyme 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ME2 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:50,879,118...50,954,257
Ensembl chr18:50,879,080...50,954,257
|
|
G |
MIR135B |
microRNA 135b |
increases expression |
EXP |
Etoposide results in increased expression of MIR135B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr 1:205,448,302...205,448,398
Ensembl chr 1:205,448,302...205,448,398
|
|
G |
MIR139 |
microRNA 139 |
increases expression |
EXP |
Etoposide results in increased expression of MIR139 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:72,615,063...72,615,130
Ensembl chr11:72,615,063...72,615,130
|
|
G |
MIR182 |
microRNA 182 |
increases expression |
EXP |
Etoposide results in increased expression of MIR182 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:129,770,383...129,770,492
Ensembl chr 7:129,770,383...129,770,492
|
|
G |
MIR196B |
microRNA 196b |
increases expression |
EXP |
Etoposide results in increased expression of MIR196B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr 7:27,169,480...27,169,563
Ensembl chr 7:27,169,480...27,169,563
|
|
G |
MIR34C |
microRNA 34c |
increases expression |
EXP |
Etoposide results in increased expression of MIR34C mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:111,513,439...111,513,515
Ensembl chr11:111,513,439...111,513,515
|
|
G |
MIR4423 |
microRNA 4423 |
increases expression |
EXP |
Etoposide results in increased expression of MIR4423 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:85,133,794...85,133,873
Ensembl chr 1:85,133,794...85,133,873
|
|
G |
MIR654 |
microRNA 654 |
increases response to substance |
EXP |
MIR654 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:20145152 |
|
NCBI chr14:101,040,219...101,040,299
Ensembl chr14:101,040,219...101,040,299
|
|
G |
MIR765 |
microRNA 765 |
increases response to substance |
EXP |
MIR765 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:20145152 |
|
NCBI chr 1:156,936,131...156,936,244
Ensembl chr 1:156,936,131...156,936,244
|
|
G |
MLANA |
melan-A |
affects response to substance |
EXP |
MLANA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:5,890,889...5,910,606
Ensembl chr 9:5,890,889...5,910,606
|
|
G |
MLLT11 |
MLLT11 transcription factor 7 cofactor |
affects response to substance |
EXP |
MLLT11 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:151,060,397...151,069,544
Ensembl chr 1:151,060,397...151,069,544
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
decreases expression multiple interactions |
EXP |
Etoposide results in decreased expression of MMP1 protein pifithrin inhibits the reaction [Etoposide results in decreased expression of MMP1 protein] |
CTD |
PMID:18557930 |
|
NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160
|
|
G |
MOCOS |
molybdenum cofactor sulfurase |
affects response to substance |
EXP |
MOCOS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:36,187,497...36,272,157
Ensembl chr18:36,187,497...36,272,157
|
|
G |
MPO |
myeloperoxidase |
increases metabolic processing |
EXP |
MPO protein results in increased metabolism of Etoposide |
CTD |
PMID:16841962 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MPZL1 |
myelin protein zero like 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of MPZL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:167,721,982...167,791,919
Ensembl chr 1:167,721,192...167,791,919
|
|
G |
MR1 |
major histocompatibility complex, class I-related |
increases expression affects expression |
EXP |
Etoposide results in increased expression of MR1 mRNA Etoposide affects the expression of MR1 mRNA |
CTD |
PMID:21527772 PMID:25811541 |
|
NCBI chr 1:181,033,387...181,061,938
Ensembl chr 1:181,033,374...181,061,938
|
|
G |
MRAS |
muscle RAS oncogene homolog |
decreases expression |
ISO |
Etoposide results in decreased expression of MRAS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:138,347,648...138,405,535
Ensembl chr 3:138,347,648...138,405,534
|
|
G |
MRC1 |
mannose receptor C-type 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MRC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:17,809,348...17,911,164
Ensembl chr10:17,809,348...17,911,164
|
|
G |
MRM2 |
mitochondrial rRNA methyltransferase 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of MRM2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:2,234,195...2,242,205
Ensembl chr 7:2,234,195...2,242,205
|
|
G |
MSC |
musculin |
decreases expression |
ISO |
Etoposide results in decreased expression of MSC mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:71,841,560...71,844,412
Ensembl chr 8:71,841,560...71,844,412
|
|
G |
MSH6 |
mutS homolog 6 |
decreases expression |
EXP |
Etoposide results in decreased expression of MSH6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:47,783,145...47,810,101
Ensembl chr 2:47,695,530...47,810,063
|
|
G |
MT-ND4 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 |
increases expression |
EXP |
Etoposide results in increased expression of ND4 mRNA |
CTD |
PMID:26259609 |
|
NCBI chr MT:10,760...12,137
Ensembl chr MT:10,760...12,137
|
|
G |
MT2A |
metallothionein 2A |
multiple interactions decreases expression |
EXP |
XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein] |
CTD |
PMID:28507149 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MTHFD2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Etoposide results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:74,198,615...74,217,565
Ensembl chr 2:74,186,172...74,217,565
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
increases phosphorylation |
EXP |
Etoposide results in increased phosphorylation of MTOR protein |
CTD |
PMID:27769712 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MTUS1 |
microtubule associated scaffold protein 1 |
affects response to substance |
EXP |
MTUS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:17,643,802...17,801,521
Ensembl chr 8:17,643,795...17,801,094
|
|
G |
MXI1 |
MAX interactor 1, dimerization protein |
affects response to substance |
EXP |
MXI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:110,207,605...110,287,365
Ensembl chr10:110,207,605...110,287,365
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression increases response to substance multiple interactions |
EXP |
Etoposide results in decreased expression of MYC; Etoposide results in decreased expression of MYC mRNA MYC protein results in increased susceptibility to Etoposide MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] |
CTD |
PMID:9454737 PMID:21324178 PMID:21527772 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
MYCN |
MYCN proto-oncogene, bHLH transcription factor |
multiple interactions decreases response to substance |
EXP |
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide MYCN protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10348353 |
|
NCBI chr 2:15,940,550...15,947,004
Ensembl chr 2:15,940,550...15,947,007
|
|
G |
MYH7 |
myosin heavy chain 7 |
decreases expression |
EXP |
Etoposide results in decreased expression of MYH7 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660
|
|
G |
MYL2 |
myosin light chain 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of MYL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr12:110,910,845...110,921,449
Ensembl chr12:110,910,819...110,921,443
|
|
G |
MYL3 |
myosin light chain 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of MYL3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:46,857,872...46,882,182
Ensembl chr 3:46,835,111...46,882,178
|
|
G |
MYOM2 |
myomesin 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of MYOM2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:2,045,046...2,145,456
Ensembl chr 8:2,045,046...2,165,552
|
|
G |
MYOT |
myotilin |
increases expression |
EXP |
Etoposide results in increased expression of MYOT mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 5:137,867,860...137,887,851
Ensembl chr 5:137,867,858...137,887,851
|
|
G |
MYT1 |
myelin transcription factor 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of MYT1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr20:64,164,452...64,242,253
Ensembl chr20:64,102,394...64,242,253
|
|
G |
NABP2 |
nucleic acid binding protein 2 |
multiple interactions increases acetylation |
EXP |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Etoposide results in increased acetylation of NABP2 protein] |
CTD |
PMID:26170237 |
|
NCBI chr12:56,222,015...56,229,854
Ensembl chr12:56,222,015...56,229,854
|
|
G |
NAP1L1 |
nucleosome assembly protein 1 like 1 |
affects response to substance |
EXP |
NAP1L1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:76,036,585...76,084,685
Ensembl chr12:76,036,585...76,084,735
|
|
G |
NCK2 |
NCK adaptor protein 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:105,744,453...105,894,272
Ensembl chr 2:105,744,912...105,894,274
|
|
G |
NECTIN2 |
nectin cell adhesion molecule 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NECTIN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:44,846,297...44,889,223
Ensembl chr19:44,846,175...44,889,223
|
|
G |
NEDD9 |
neural precursor cell expressed, developmentally down-regulated 9 |
affects response to substance |
EXP |
NEDD9 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:11,183,298...11,382,348
Ensembl chr 6:11,183,298...11,382,348
|
|
G |
NEK2 |
NIMA related kinase 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of NEK2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:211,658,256...211,675,621
Ensembl chr 1:211,658,657...211,675,630
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
decreases response to substance multiple interactions |
EXP |
NFE2L2 mRNA results in decreased susceptibility to Etoposide; NFE2L2 protein results in decreased susceptibility to Etoposide NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:26708503 PMID:27982581 PMID:33148531 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:23396362 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions increases degradation |
EXP |
wortmannin inhibits the reaction [Etoposide results in increased degradation of NFKBIA protein] |
CTD |
PMID:12637521 PMID:17935137 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NHERF1 |
NHERF family PDZ scaffold protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of NHERF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:74,748,628...74,769,353
Ensembl chr17:74,748,628...74,769,353
|
|
G |
NIBAN1 |
niban apoptosis regulator 1 |
affects response to substance |
EXP |
NIBAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:184,791,032...184,974,508
Ensembl chr 1:184,790,724...184,974,508
|
|
G |
NIT2 |
nitrilase family member 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of NIT2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 3:100,334,757...100,361,635
Ensembl chr 3:100,334,739...100,361,635
|
|
G |
NMT2 |
N-myristoyltransferase 2 |
affects response to substance |
EXP |
NMT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:15,105,700...15,168,693
Ensembl chr10:15,102,584...15,168,693
|
|
G |
NOS2 |
nitric oxide synthase 2 |
increases expression |
ISO EXP |
Etoposide results in increased expression of NOS2 mRNA Etoposide results in increased expression of NOS2 protein |
CTD |
PMID:15135310 PMID:26259609 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPAS1 |
neuronal PAS domain protein 1 |
increases expression |
EXP |
Etoposide results in increased expression of NPAS1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:47,019,837...47,045,775
Ensembl chr19:47,019,837...47,045,775
|
|
G |
NPNT |
nephronectin |
increases expression |
ISO |
Etoposide results in increased expression of NPNT mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:105,895,471...105,971,671
Ensembl chr 4:105,894,775...106,004,027
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
affects response to substance increases expression multiple interactions |
EXP ISO |
NQO1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NQO1 mRNA HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] |
CTD |
PMID:16217747 PMID:20980392 PMID:29397400 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:30,304,206...30,309,390
Ensembl chr X:30,304,206...30,309,390
|
|
G |
NR1H2 |
nuclear receptor subfamily 1 group H member 2 |
affects localization affects response to substance multiple interactions |
EXP |
Etoposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Etoposide Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr19:50,376,457...50,383,388
Ensembl chr19:50,329,653...50,383,388
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions affects response to substance increases expression |
EXP |
Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide results in increased expression of and affects the localization of NR1H3 protein; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] NR1H3 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NR1H3 mRNA |
CTD |
PMID:25914138 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
affects response to substance multiple interactions increases activity |
EXP |
NR1I2 protein affects the susceptibility to Etoposide [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17279585 PMID:25455453 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NRAP |
nebulin related anchoring protein |
decreases expression |
EXP |
Etoposide results in decreased expression of NRAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:113,588,714...113,664,041
Ensembl chr10:113,588,714...113,664,070
|
|
G |
NRG1 |
neuregulin 1 |
increases expression |
EXP |
Etoposide results in increased expression of NRG1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:31,639,245...32,774,046
Ensembl chr 8:31,639,222...32,855,666
|
|
G |
NRIP1 |
nuclear receptor interacting protein 1 |
affects response to substance decreases expression |
EXP |
NRIP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NRIP1 mRNA; Etoposide results in decreased expression of NRIP1 protein |
CTD |
PMID:16217747 PMID:25914138 |
|
NCBI chr21:14,961,235...15,065,936
Ensembl chr21:14,961,235...15,065,936
|
|
G |
NUPR1 |
nuclear protein 1, transcriptional regulator |
affects response to substance decreases expression |
EXP ISO |
NUPR1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NUPR1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr16:28,532,708...28,538,974
Ensembl chr16:28,532,708...28,539,008
|
|
G |
OAT |
ornithine aminotransferase |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of OAT protein |
CTD |
PMID:29733421 |
|
NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976
|
|
G |
OCA2 |
OCA2 melanosomal transmembrane protein |
affects response to substance |
EXP |
OCA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:27,719,008...28,099,315
Ensembl chr15:27,754,875...28,099,315
|
|
G |
OGG1 |
8-oxoguanine DNA glycosylase |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of OGG1 mRNA wogonin inhibits the reaction [Etoposide results in decreased expression of OGG1 mRNA] |
CTD |
PMID:23872129 |
|
NCBI chr 3:9,749,952...9,783,108
Ensembl chr 3:9,749,944...9,788,219
|
|
G |
P2RX7 |
purinergic receptor P2X 7 |
increases expression |
ISO |
Etoposide results in increased expression of P2RX7 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:121,132,876...121,188,032
Ensembl chr12:121,132,819...121,188,032
|
|
G |
PABPC1 |
poly(A) binding protein cytoplasmic 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PABPC1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 8:100,702,916...100,722,088
Ensembl chr 8:100,685,816...100,722,809
|
|
G |
PALB2 |
partner and localizer of BRCA2 |
decreases expression |
EXP |
Etoposide results in decreased expression of PALB2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr16:23,603,165...23,641,310
Ensembl chr16:23,603,160...23,641,321
|
|
G |
PAPSS2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
increases expression |
ISO |
Etoposide results in increased expression of PAPSS2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:87,659,878...87,747,705
Ensembl chr10:87,659,613...87,747,705
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases degradation |
ISO EXP |
Etoposide results in increased cleavage of PARP1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein] |
CTD |
PMID:8840993 PMID:9454737 PMID:12690110 PMID:16014620 PMID:16545138 PMID:16799960 PMID:16807353 PMID:16844113 PMID:17516866 PMID:17935137 PMID:20457658 PMID:21801448 PMID:25447644 PMID:26259609 PMID:28507149 PMID:30890322 PMID:33148531 More...
|
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PBK |
PDZ binding kinase |
affects response to substance |
EXP |
PBK protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:27,809,624...27,837,817
Ensembl chr 8:27,809,624...27,838,082
|
|
G |
PCBP2 |
poly(rC) binding protein 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PCBP2 protein |
CTD |
PMID:29733421 |
|
NCBI chr12:53,452,102...53,481,162
Ensembl chr12:53,452,102...53,481,162
|
|
G |
PCBP4 |
poly(rC) binding protein 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of PCBP4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:51,957,454...51,967,466
Ensembl chr 3:51,957,454...51,974,016
|
|
G |
PCK2 |
phosphoenolpyruvate carboxykinase 2, mitochondrial |
decreases expression |
ISO |
Etoposide results in decreased expression of PCK2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:24,094,171...24,104,125
Ensembl chr14:24,094,053...24,110,598
|
|
G |
PDE2A |
phosphodiesterase 2A |
decreases expression |
ISO |
Etoposide results in decreased expression of PDE2A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:72,576,141...72,674,422
Ensembl chr11:72,576,141...72,674,591
|
|
G |
PDE4B |
phosphodiesterase 4B |
affects response to substance |
EXP |
PDE4B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:65,792,510...66,374,579
Ensembl chr 1:65,792,514...66,374,579
|
|
G |
PDGFC |
platelet derived growth factor C |
affects response to substance |
EXP |
PDGFC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:156,760,454...156,971,799
Ensembl chr 4:156,760,454...156,971,799
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
multiple interactions |
ISO |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of PDIA3 protein |
CTD |
PMID:24478030 |
|
NCBI chr15:43,746,438...43,773,278
Ensembl chr15:43,746,394...43,773,279
|
|
G |
PDK1 |
pyruvate dehydrogenase kinase 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of PDK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:172,555,373...172,724,312
Ensembl chr 2:172,555,373...172,608,669
|
|
G |
PDK4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Etoposide results in increased expression of PDK4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
|
|
G |
PDLIM3 |
PDZ and LIM domain 3 |
increases expression |
EXP |
Etoposide results in increased expression of PDLIM3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 4:185,500,660...185,535,507
Ensembl chr 4:185,500,660...185,535,507
|
|
G |
PELO |
pelota mRNA surveillance and ribosome rescue factor |
decreases expression |
EXP |
Etoposide results in decreased expression of PELO mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:52,787,916...52,804,044
Ensembl chr 5:52,787,916...52,804,044
|
|
G |
PERP |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
Etoposide results in increased expression of PERP mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr 6:138,088,505...138,107,419
Ensembl chr 6:138,088,505...138,107,419
|
|
G |
PHGDH |
phosphoglycerate dehydrogenase |
affects response to substance |
EXP |
PHGDH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:119,711,934...119,744,215
Ensembl chr 1:119,648,411...119,744,218
|
|
G |
PHLDA3 |
pleckstrin homology like domain family A member 3 |
increases expression |
ISO |
Etoposide results in increased expression of PHLDA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:201,464,278...201,469,188
Ensembl chr 1:201,464,278...201,469,237
|
|
G |
PIGA |
phosphatidylinositol glycan anchor biosynthesis class A |
multiple interactions |
EXP |
[Cisplatin co-treated with Etoposide] results in increased mutagenesis of PIGA |
CTD |
PMID:21826740 |
|
NCBI chr X:15,319,451...15,335,554
Ensembl chr X:15,319,452...15,335,554
|
|
G |
PIP5K1B |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
affects response to substance |
EXP |
PIP5K1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:68,705,240...69,009,176
Ensembl chr 9:68,705,240...69,009,176
|
|
G |
PLAU |
plasminogen activator, urokinase |
increases expression |
EXP |
Etoposide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
PLK1 |
polo like kinase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PLK1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:23,678,889...23,690,367
Ensembl chr16:23,677,656...23,690,367
|
|
G |
PLK2 |
polo like kinase 2 |
increases expression |
EXP |
Etoposide results in increased expression of PLK2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139
|
|
G |
PLK3 |
polo like kinase 3 |
increases expression |
EXP |
Etoposide results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:44,800,377...44,805,990
Ensembl chr 1:44,800,377...44,805,990
|
|
G |
PLP1 |
proteolipid protein 1 |
affects response to substance |
EXP |
PLP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:103,776,506...103,792,619
Ensembl chr X:103,773,718...103,792,619
|
|
G |
PLPP2 |
phospholipid phosphatase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of PLPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:281,043...291,403
Ensembl chr19:281,040...291,403
|
|
G |
PM20D1 |
peptidase M20 domain containing 1 |
increases expression |
ISO |
Etoposide results in increased expression of PM20D1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:205,828,025...205,850,132
Ensembl chr 1:205,828,025...205,850,132
|
|
G |
PMAIP1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
EXP |
Etoposide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:21801448 |
|
NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305
|
|
G |
PMEL |
premelanosome protein |
affects response to substance |
EXP |
PMEL protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:55,954,105...55,966,709
Ensembl chr12:55,954,105...55,973,317
|
|
G |
PMP2 |
peripheral myelin protein 2 |
affects response to substance |
EXP |
PMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:81,440,326...81,447,439
Ensembl chr 8:81,440,326...81,447,439
|
|
G |
PMP22 |
peripheral myelin protein 22 |
affects response to substance |
EXP |
PMP22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:15,229,779...15,265,326
Ensembl chr17:15,229,773...15,272,292
|
|
G |
POLQ |
DNA polymerase theta |
decreases response to substance |
ISO |
POLQ results in decreased susceptibility to Etoposide |
CTD |
PMID:21883722 |
|
NCBI chr 3:121,431,431...121,545,988
Ensembl chr 3:121,431,431...121,545,988
|
|
G |
POLR1H |
RNA polymerase I subunit H |
decreases response to substance multiple interactions |
EXP |
POLR1H protein results in decreased susceptibility to Etoposide Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:14726695 |
|
NCBI chr 6:30,060,062...30,064,907
Ensembl chr 6:30,058,899...30,064,909
|
|
G |
POMZP3 |
POM121 and ZP3 fusion |
affects response to substance |
EXP |
POMZP3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:76,609,986...76,627,279
Ensembl chr 7:76,609,986...76,627,279
|
|
G |
POSTN |
periostin |
increases expression |
EXP |
Etoposide results in increased expression of POSTN mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:37,562,585...37,598,768
Ensembl chr13:37,562,583...37,598,844
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
increases expression |
EXP |
Etoposide results in increased expression of POU5F1 mRNA; Etoposide results in increased expression of POU5F1 protein |
CTD |
PMID:33969609 |
|
NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of PPARGC1A mRNA Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:26259609 PMID:30818834 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPARGC1B |
PPARG coactivator 1 beta |
increases expression |
EXP |
Etoposide results in increased expression of PPARGC1B mRNA |
CTD |
PMID:26259609 |
|
NCBI chr 5:149,730,310...149,857,959
Ensembl chr 5:149,730,298...149,855,022
|
|
G |
PPM1D |
protein phosphatase, Mg2+/Mn2+ dependent 1D |
increases expression |
EXP |
Etoposide results in increased expression of PPM1D protein |
CTD |
PMID:25078064 |
|
NCBI chr17:60,600,193...60,666,280
Ensembl chr17:60,600,193...60,666,280
|
|
G |
PPP1R13L |
protein phosphatase 1 regulatory subunit 13 like |
decreases response to substance multiple interactions increases expression |
EXP |
PPP1R13L results in decreased susceptibility to Etoposide Etoposide results in increased expression of and results in increased localization of PPP1R13L protein Etoposide results in increased expression of PPP1R13L mRNA |
CTD |
PMID:17570360 PMID:19299014 |
|
NCBI chr19:45,379,638...45,406,361
Ensembl chr19:45,379,638...45,406,349
|
|
G |
PRC1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr15:90,966,040...90,994,535
Ensembl chr15:90,966,040...90,995,629
|
|
G |
PRDX1 |
peroxiredoxin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PRDX1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:45,511,051...45,522,890
Ensembl chr 1:45,510,914...45,542,732
|
|
G |
PRKAB1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
increases expression |
EXP |
Etoposide results in increased expression of PRKAB1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:119,667,952...119,681,619
Ensembl chr12:119,667,864...119,681,624
|
|
G |
PRKCD |
protein kinase C delta |
multiple interactions |
EXP |
Etoposide results in increased cleavage of and results in increased activity of PRKCD protein |
CTD |
PMID:19662097 |
|
NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
|
|
G |
PRKCZ |
protein kinase C zeta |
increases response to substance |
EXP |
PRKCZ protein results in increased susceptibility to Etoposide |
CTD |
PMID:21863889 |
|
NCBI chr 1:2,048,504...2,185,395
Ensembl chr 1:2,050,411...2,185,395
|
|
G |
PRKDC |
protein kinase, DNA-activated, catalytic subunit |
increases phosphorylation multiple interactions |
EXP |
Etoposide results in increased phosphorylation of PRKDC protein PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein] |
CTD |
PMID:17441964 |
|
NCBI chr 8:47,773,111...47,960,136
Ensembl chr 8:47,773,111...47,960,178
|
|
G |
PRKX |
protein kinase cAMP-dependent X-linked catalytic subunit |
increases expression |
EXP |
Etoposide results in increased expression of PRKX mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:3,604,340...3,713,649
Ensembl chr X:3,604,340...3,713,649
|
|
G |
PRNP |
prion protein (Kanno blood group) |
decreases response to substance |
EXP |
PRNP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15386405 |
|
NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590
|
|
G |
PROCR |
protein C receptor |
increases expression |
EXP |
Etoposide results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr20:35,171,096...35,216,259
Ensembl chr20:35,172,072...35,216,240
|
|
G |
PSMD13 |
proteasome 26S subunit, non-ATPase 13 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PSMD13 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:236,976...252,984
Ensembl chr11:236,966...252,984
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions increases response to substance |
EXP |
PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; wortmannin inhibits the reaction [PTEN protein results in increased susceptibility to Etoposide] |
CTD |
PMID:16807353 PMID:17935137 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of PTGS2 protein PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 PMID:26259609 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PUS3 |
pseudouridine synthase 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of PUS3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr11:125,893,485...125,903,206
Ensembl chr11:125,893,485...125,903,221
|
|
G |
PYGM |
glycogen phosphorylase, muscle associated |
decreases expression |
EXP |
Etoposide results in decreased expression of PYGM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:64,746,389...64,760,715
Ensembl chr11:64,746,389...64,759,974
|
|
G |
RAB17 |
RAB17, member RAS oncogene family |
affects response to substance |
EXP |
RAB17 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:237,574,326...237,590,734
Ensembl chr 2:237,574,322...237,601,614
|
|
G |
RAB20 |
RAB20, member RAS oncogene family |
affects response to substance |
EXP |
RAB20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:110,523,066...110,561,722
Ensembl chr13:110,523,066...110,561,722
|
|
G |
RAD51 |
RAD51 recombinase |
affects localization |
ISO |
Etoposide affects the localization of RAD51 protein |
CTD |
PMID:9885240 |
|
NCBI chr15:40,694,733...40,732,340
Ensembl chr15:40,694,774...40,732,340
|
|
G |
RAD52 |
RAD52 homolog, DNA repair protein |
multiple interactions increases expression |
EXP |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein] Etoposide results in increased expression of RAD52 mRNA; Etoposide results in increased expression of RAD52 protein |
CTD |
PMID:16417649 PMID:19799994 |
|
NCBI chr12:911,736...991,122
Ensembl chr12:911,736...990,053
|
|
G |
RAD54B |
RAD54 homolog B |
multiple interactions |
ISO |
RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:33823233 |
|
NCBI chr 8:94,371,960...94,475,115
Ensembl chr 8:94,371,960...94,475,115
|
|
G |
RAD54L |
RAD54 like |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of RAD54L protein BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein] |
CTD |
PMID:16417649 |
|
NCBI chr 1:46,247,688...46,278,473
Ensembl chr 1:46,246,461...46,278,480
|
|
G |
RASIP1 |
Ras interacting protein 1 |
affects response to substance |
EXP |
RASIP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:48,720,585...48,740,610
Ensembl chr19:48,720,585...48,740,610
|
|
G |
RASSF1 |
Ras association domain family member 1 |
multiple interactions increases response to substance |
EXP |
[RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] |
CTD |
PMID:21880625 |
|
NCBI chr 3:50,329,788...50,340,836
Ensembl chr 3:50,329,782...50,340,980
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
affects response to substance decreases phosphorylation multiple interactions |
EXP |
RB1 protein affects the susceptibility to Etoposide Etoposide results in decreased phosphorylation of RB1 protein [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:9454737 PMID:17640669 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RBM17 |
RNA binding motif protein 17 |
decreases response to substance |
EXP |
RBM17 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16061639 |
|
NCBI chr10:6,089,034...6,117,447
Ensembl chr10:6,089,034...6,117,457
|
|
G |
RBM34 |
RNA binding motif protein 34 |
decreases expression |
EXP |
Etoposide results in decreased expression of RBM34 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:235,131,183...235,161,250
Ensembl chr 1:235,131,183...235,161,283
|
|
G |
RCAN1 |
regulator of calcineurin 1 |
affects response to substance |
EXP |
RCAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr21:34,516,442...34,615,113
Ensembl chr21:34,513,142...34,615,113
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RETSAT |
retinol saturase |
increases expression |
EXP |
Etoposide results in increased expression of RETSAT mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:85,341,955...85,354,528
Ensembl chr 2:85,341,955...85,354,531
|
|
G |
RFC1 |
replication factor C subunit 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of RFC1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:39,287,456...39,366,362
Ensembl chr 4:39,287,456...39,366,375
|
|
G |
RGCC |
regulator of cell cycle |
increases expression |
EXP |
Etoposide results in increased expression of RGCC mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:41,457,550...41,470,871
Ensembl chr13:41,457,550...41,470,871
|
|
G |
RIPK2 |
receptor interacting serine/threonine kinase 2 |
multiple interactions increases expression |
EXP |
Estradiol inhibits the reaction [Etoposide results in increased expression of RIPK2 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 8:89,757,816...89,791,064
Ensembl chr 8:89,757,806...89,791,064
|
|
G |
RIPPLY3 |
ripply transcriptional repressor 3 |
increases expression |
EXP |
Etoposide results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr21:37,006,150...37,019,662
Ensembl chr21:37,006,150...37,019,662
|
|
G |
RNF113A |
ring finger protein 113A |
decreases expression |
EXP |
Etoposide results in decreased expression of RNF113A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr X:119,870,475...119,871,733
Ensembl chr X:119,870,475...119,871,733
|
|
G |
ROBO1 |
roundabout guidance receptor 1 |
affects response to substance |
EXP |
ROBO1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:78,597,239...79,767,998
Ensembl chr 3:78,597,239...79,767,998
|
|
G |
ROBO3 |
roundabout guidance receptor 3 |
increases expression |
EXP |
Etoposide results in increased expression of ROBO3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:124,865,432...124,881,471
Ensembl chr11:124,865,432...124,881,471
|
|
G |
ROPN1 |
rhophilin associated tail protein 1 |
affects response to substance |
EXP |
ROPN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:123,969,015...123,992,124
Ensembl chr 3:123,968,521...123,992,178
|
|
G |
RPL6 |
ribosomal protein L6 |
decreases response to substance |
EXP |
RPL6 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15846068 |
|
NCBI chr12:112,405,181...112,418,835
Ensembl chr12:112,405,189...112,418,838
|
|
G |
RPS27L |
ribosomal protein S27 like |
increases expression |
EXP |
Etoposide results in increased expression of RPS27L protein |
CTD |
PMID:18056458 |
|
NCBI chr15:63,148,249...63,157,477
Ensembl chr15:63,125,872...63,158,021
|
|
G |
RPS6 |
ribosomal protein S6 |
increases phosphorylation |
EXP |
Etoposide results in increased phosphorylation of RPS6 protein |
CTD |
PMID:23396362 |
|
NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
|
|
G |
RRAS |
RAS related |
increases expression |
EXP |
Etoposide results in increased expression of RRAS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:49,635,292...49,640,143
Ensembl chr19:49,635,292...49,640,143
|
|
G |
RRM2B |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
EXP |
Etoposide results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 8:102,204,501...102,238,961
Ensembl chr 8:102,204,502...102,238,961
|
|
G |
RTKN |
rhotekin |
increases expression |
ISO |
Etoposide results in increased expression of RTKN mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:74,425,835...74,441,937
Ensembl chr 2:74,425,835...74,442,422
|
|
G |
RUNX1 |
RUNX family transcription factor 1 |
increases response to substance increases mutagenesis |
EXP |
RUNX1 gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of RUNX1 gene |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr21:34,787,801...35,049,302
Ensembl chr21:34,787,801...36,004,667
|
|
G |
RUNX3 |
RUNX family transcription factor 3 |
increases response to substance |
EXP |
RUNX3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15756676 |
|
NCBI chr 1:24,899,511...24,965,138
Ensembl chr 1:24,899,511...24,965,121
|
|
G |
RXRA |
retinoid X receptor alpha |
multiple interactions |
EXP |
Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]] |
CTD |
PMID:25914138 |
|
NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585
|
|
G |
RYR2 |
ryanodine receptor 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of RYR2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:237,042,184...237,833,988
Ensembl chr 1:237,042,184...237,833,988
|
|
G |
S100P |
S100 calcium binding protein P |
affects response to substance increases response to substance |
EXP |
S100P protein affects the susceptibility to Etoposide S100P protein results in increased susceptibility to Etoposide |
CTD |
PMID:16217747 PMID:18636193 |
|
NCBI chr 4:6,693,878...6,697,170
Ensembl chr 4:6,693,878...6,697,170
|
|
G |
SCN3B |
sodium voltage-gated channel beta subunit 3 |
increases expression |
ISO |
Etoposide results in increased expression of SCN3B mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:123,629,188...123,654,624
Ensembl chr11:123,629,187...123,655,244
|
|
G |
SCN4B |
sodium voltage-gated channel beta subunit 4 |
increases expression |
EXP |
Etoposide results in increased expression of SCN4B mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:118,133,377...118,152,823
Ensembl chr11:118,133,377...118,152,888
|
|
G |
SDC1 |
syndecan 1 |
increases expression |
EXP |
Etoposide results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:20,200,797...20,225,475
Ensembl chr 2:20,200,797...20,225,433
|
|
G |
SDHAF1 |
succinate dehydrogenase complex assembly factor 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of SDHAF1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr19:35,995,188...35,996,312
Ensembl chr19:35,995,188...35,996,312
|
|
G |
SERPINE2 |
serpin family E member 2 |
increases expression |
ISO |
Etoposide results in increased expression of SERPINE2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:223,975,045...224,039,286
Ensembl chr 2:223,975,045...224,039,318
|
|
G |
SESN1 |
sestrin 1 |
increases expression |
EXP |
Etoposide results in increased expression of SESN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:108,984,309...109,094,846
Ensembl chr 6:108,984,309...109,094,846
|
|
G |
SFN |
stratifin |
increases expression |
EXP |
Etoposide results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456
|
|
G |
SLBP |
stem-loop histone mRNA binding protein |
decreases expression |
EXP |
Etoposide results in decreased expression of SLBP mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:1,692,731...1,712,319
Ensembl chr 4:1,692,731...1,712,344
|
|
G |
SLC16A6 |
solute carrier family 16 member 6 |
affects response to substance |
EXP |
SLC16A6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:68,267,026...68,291,479
Ensembl chr17:68,267,026...68,291,267
|
|
G |
SLC1A5 |
solute carrier family 1 member 5 |
decreases expression |
EXP |
Etoposide results in decreased expression of SLC1A5 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr19:46,774,883...46,788,594
Ensembl chr19:46,774,883...46,788,594
|
|
G |
SLC22A18 |
solute carrier family 22 member 18 |
affects response to substance |
EXP |
SLC22A18 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:2,899,691...2,925,246
Ensembl chr11:2,899,721...2,925,246
|
|
G |
SLC27A3 |
solute carrier family 27 member 3 |
affects response to substance |
EXP |
SLC27A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:153,775,407...153,780,157
Ensembl chr 1:153,774,354...153,780,157
|
|
G |
SLC2A6 |
solute carrier family 2 member 6 |
increases expression |
EXP |
Etoposide results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:133,471,094...133,479,099
Ensembl chr 9:133,471,094...133,479,127
|
|
G |
SLC35F2 |
solute carrier family 35 member F2 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC35F2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:107,790,991...107,858,787
Ensembl chr11:107,790,991...107,928,293
|
|
G |
SLC45A3 |
solute carrier family 45 member 3 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of SLC45A3 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr 1:205,657,851...205,680,509
Ensembl chr 1:205,657,851...205,680,509
|
|
G |
SLC4A11 |
solute carrier family 4 member 11 |
increases expression |
ISO |
Etoposide results in increased expression of SLC4A11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:3,227,417...3,239,559
Ensembl chr20:3,227,417...3,239,559
|
|
G |
SLC7A11 |
solute carrier family 7 member 11 |
affects response to substance |
EXP |
SLC7A11 protein affects the susceptibility to Etoposide |
CTD |
PMID:31226288 |
|
NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349
|
|
G |
SLC7A3 |
solute carrier family 7 member 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC7A3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:70,925,579...70,931,096
Ensembl chr X:70,925,579...70,931,125
|
|
G |
SLC7A5 |
solute carrier family 7 member 5 |
affects response to substance |
EXP |
SLC7A5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:87,830,023...87,869,507
Ensembl chr16:87,830,023...87,869,507
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
decreases expression |
EXP |
Etoposide results in decreased expression of SLC8A1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:40,097,270...40,512,435
Ensembl chr 2:40,097,270...40,611,053
|
|
G |
SLCO2B1 |
solute carrier organic anion transporter family member 2B1 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
EXP |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:22363485 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMPDL3A |
sphingomyelin phosphodiesterase acid like 3A |
affects response to substance |
EXP |
SMPDL3A protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:122,789,258...122,809,720
Ensembl chr 6:122,789,049...122,809,720
|
|
G |
SOD2 |
superoxide dismutase 2 |
increases expression decreases response to substance |
EXP |
Etoposide results in increased expression of SOD2 protein SOD2 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10759716 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOHLH1 |
spermatogenesis and oogenesis specific basic helix-loop-helix 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of SOHLH1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr 9:135,693,407...135,702,112
Ensembl chr 9:135,693,407...135,704,498
|
|
G |
SORBS1 |
sorbin and SH3 domain containing 1 |
affects response to substance |
EXP |
SORBS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:95,311,773...95,561,371
Ensembl chr10:95,311,771...95,561,414
|
|
G |
SORBS2 |
sorbin and SH3 domain containing 2 |
affects response to substance |
EXP |
SORBS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:185,585,523...185,956,372
Ensembl chr 4:185,585,444...185,956,652
|
|
G |
SORT1 |
sortilin 1 |
affects response to substance |
EXP |
SORT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:109,309,575...109,397,918
Ensembl chr 1:109,309,568...109,397,918
|
|
G |
SOX10 |
SRY-box transcription factor 10 |
affects response to substance |
EXP |
SOX10 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr22:37,972,312...37,984,555
Ensembl chr22:37,970,686...37,987,422
|
|
G |
SOX2 |
SRY-box transcription factor 2 |
multiple interactions |
EXP |
FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
|
|
G |
SP1 |
Sp1 transcription factor |
increases phosphorylation increases expression increases activity multiple interactions |
EXP ISO |
Etoposide results in increased phosphorylation of SP1 protein Etoposide results in increased expression of SP1 mRNA Etoposide results in increased activity of SP1 protein cordycepin inhibits the reaction [Etoposide results in increased activity of SP1 protein]; cordycepin inhibits the reaction [Etoposide results in increased expression of SP1 mRNA] PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of SP1 protein] |
CTD |
PMID:17441964 PMID:23690541 |
|
NCBI chr12:53,380,176...53,416,446
Ensembl chr12:53,380,176...53,416,446
|
|
G |
SPATA18 |
spermatogenesis associated 18 |
increases expression |
EXP |
Etoposide results in increased expression of SPATA18 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr 4:52,051,304...52,097,299
Ensembl chr 4:52,051,304...52,097,299
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
affects response to substance decreases expression |
EXP ISO |
SPP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of SPP1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SPTSSA |
serine palmitoyltransferase small subunit A |
affects response to substance |
EXP |
SPTSSA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:34,432,788...34,462,240
Ensembl chr14:34,432,788...34,462,240
|
|
G |
SRXN1 |
sulfiredoxin 1 |
increases expression multiple interactions |
ISO EXP |
Etoposide results in increased expression of SRXN1 mRNA; Etoposide results in increased expression of SRXN1 protein NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein] |
CTD |
PMID:22003191 PMID:27358234 PMID:27982581 |
|
NCBI chr20:646,615...653,200
Ensembl chr20:646,615...653,200
|
|
G |
ST3GAL5 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 5 |
decreases response to substance |
ISO |
ST3GAL5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16571667 |
|
NCBI chr 2:85,837,120...85,889,034
Ensembl chr 2:85,837,120...85,905,199
|
|
G |
ST6GALNAC2 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 |
affects response to substance |
EXP |
ST6GALNAC2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:76,565,377...76,585,860
Ensembl chr17:76,565,377...76,586,956
|
|
G |
ST7 |
suppression of tumorigenicity 7 |
affects response to substance |
EXP |
ST7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:116,953,501...117,230,176
Ensembl chr 7:116,953,238...117,230,176
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
[STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:18649362 |
|
NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960
|
|
G |
STC1 |
stanniocalcin 1 |
increases expression |
EXP |
Etoposide results in increased expression of STC1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:23,841,929...23,854,806
Ensembl chr 8:23,841,929...23,854,806
|
|
G |
STIP1 |
stress induced phosphoprotein 1 |
increases expression |
ISO |
Etoposide results in increased expression of STIP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
|
|
G |
STK17A |
serine/threonine kinase 17a |
increases expression |
ISO |
Etoposide results in increased expression of STK17A mRNA |
CTD |
PMID:21489989 |
|
NCBI chr 7:43,583,108...43,627,379
Ensembl chr 7:43,582,758...43,650,713
|
|
G |
STMN1 |
stathmin 1 |
affects response to substance |
EXP |
STMN1 affects the susceptibility to Etoposide |
CTD |
PMID:17172428 |
|
NCBI chr 1:25,884,179...25,906,880
Ensembl chr 1:25,884,181...25,906,991
|
|
G |
STMN2 |
stathmin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of STMN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:79,611,117...79,666,158
Ensembl chr 8:79,611,117...79,666,158
|
|
G |
STOM |
stomatin |
increases expression |
EXP |
Etoposide results in increased expression of STOM mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:121,338,987...121,370,250
Ensembl chr 9:121,338,987...121,370,304
|
|
G |
SYTL1 |
synaptotagmin like 1 |
increases expression |
ISO |
Etoposide results in increased expression of SYTL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:27,342,022...27,353,932
Ensembl chr 1:27,342,020...27,353,937
|
|
G |
TAP1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
EXP |
Etoposide results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 PMID:21527772 |
|
NCBI chr 6:32,845,209...32,853,704
Ensembl chr 6:32,845,209...32,853,816
|
|
G |
TAX1BP3 |
Tax1 binding protein 3 |
increases expression |
EXP |
Etoposide results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:3,662,895...3,668,578
Ensembl chr17:3,662,895...3,668,679
|
|
G |
TBC1D8 |
TBC1 domain family member 8 |
increases expression |
ISO |
Etoposide results in increased expression of TBC1D8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:101,007,228...101,151,382
Ensembl chr 2:101,007,228...101,252,866
|
|
G |
TBL1X |
transducin beta like 1 X-linked |
decreases expression |
ISO |
Etoposide results in decreased expression of TBL1X mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:9,463,295...9,719,740
Ensembl chr X:9,463,320...9,741,037
|
|
G |
TBPL1 |
TATA-box binding protein like 1 |
affects localization |
ISO |
Etoposide affects the localization of TBPL1 protein |
CTD |
PMID:17085973 |
|
NCBI chr 6:133,952,174...133,990,432
Ensembl chr 6:133,952,170...133,990,432
|
|
G |
TCAP |
titin-cap |
decreases expression |
EXP |
Etoposide results in decreased expression of TCAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr17:39,665,349...39,666,554
Ensembl chr17:39,665,349...39,666,554
|
|
G |
TCFL5 |
transcription factor like 5 |
affects response to substance |
EXP |
TCFL5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:62,841,005...62,861,822
Ensembl chr20:62,841,005...62,861,822
|
|
G |
TCP1 |
t-complex 1 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of TCP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 6:159,778,498...159,789,602
Ensembl chr 6:159,778,498...159,789,703
|
|
G |
TDRD3 |
tudor domain containing 3 |
affects response to substance |
EXP |
TDRD3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:60,395,533...60,573,879
Ensembl chr13:60,396,457...60,573,878
|
|
G |
TENT5A |
terminal nucleotidyltransferase 5A |
affects response to substance |
EXP |
TENT5A protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:81,745,730...81,752,681
Ensembl chr 6:81,491,439...81,752,774
|
|
G |
TEX264 |
testis expressed 264, ER-phagy receptor |
decreases expression |
ISO |
Etoposide results in decreased expression of TEX264 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:51,671,252...51,704,323
Ensembl chr 3:51,662,693...51,704,323
|
|
G |
TFAM |
transcription factor A, mitochondrial |
increases expression |
EXP |
Etoposide results in increased expression of TFAM mRNA |
CTD |
PMID:26259609 |
|
NCBI chr10:58,385,410...58,399,220
Ensembl chr10:58,385,345...58,399,220
|
|
G |
TFAP2A |
transcription factor AP-2 alpha |
affects response to substance increases response to substance |
EXP |
TFAP2A protein affects the susceptibility to Etoposide TFAP2A protein results in increased susceptibility to Etoposide |
CTD |
PMID:16204029 PMID:16217747 |
|
NCBI chr 6:10,396,677...10,419,659
Ensembl chr 6:10,393,186...10,419,659
|
|
G |
TFEC |
transcription factor EC |
decreases expression |
EXP |
Etoposide results in decreased expression of TFEC mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:115,935,152...116,159,896
Ensembl chr 7:115,935,148...116,159,896
|
|
G |
TFF3 |
trefoil factor 3 |
affects response to substance |
EXP |
TFF3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr21:42,311,667...42,315,409
Ensembl chr21:42,311,667...42,315,409
|
|
G |
TFPI |
tissue factor pathway inhibitor |
affects response to substance |
EXP |
TFPI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
|
|
G |
TFPI2 |
tissue factor pathway inhibitor 2 |
affects response to substance |
EXP |
TFPI2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:93,885,396...93,890,753
Ensembl chr 7:93,885,396...93,890,753
|
|
G |
TFRC |
transferrin receptor |
decreases expression multiple interactions |
EXP |
Etoposide results in decreased expression of TFRC mRNA; Etoposide results in decreased expression of TFRC protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of TFRC protein] |
CTD |
PMID:33969609 |
|
NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153
|
|
G |
TGDS |
TDP-glucose 4,6-dehydratase |
affects response to substance |
EXP |
TGDS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:94,574,054...94,596,273
Ensembl chr13:94,574,054...94,596,242
|
|
G |
TGFA |
transforming growth factor alpha |
increases expression |
EXP |
Etoposide results in increased expression of TGFA mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TGIF2 |
TGFB induced factor homeobox 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of TGIF2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:36,573,464...36,593,950
Ensembl chr20:36,573,488...36,593,950
|
|
G |
THBS4 |
thrombospondin 4 |
increases expression |
EXP |
Etoposide results in increased expression of THBS4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 5:79,991,332...80,083,287
Ensembl chr 5:79,991,311...80,083,287
|
|
G |
TIPIN |
TIMELESS interacting protein |
decreases expression |
EXP |
Etoposide results in decreased expression of TIPIN mRNA |
CTD |
PMID:24211769 |
|
NCBI chr15:66,336,191...66,386,717
Ensembl chr15:66,336,191...66,386,746
|
|
G |
TM7SF3 |
transmembrane 7 superfamily member 3 |
increases expression |
ISO |
Etoposide results in increased expression of TM7SF3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:26,971,579...27,014,384
Ensembl chr12:26,971,579...27,014,434
|
|
G |
TMBIM4 |
transmembrane BAX inhibitor motif containing 4 |
increases expression |
ISO |
Etoposide results in increased expression of TMBIM4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:66,135,846...66,169,996
Ensembl chr12:66,135,846...66,170,027
|
|
G |
TMC6 |
transmembrane channel like 6 |
affects response to substance |
EXP |
TMC6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:78,107,397...78,132,427
Ensembl chr17:78,107,397...78,132,407
|
|
G |
TMEM185B |
transmembrane protein 185B |
decreases expression |
EXP |
Etoposide results in decreased expression of TMEM185B mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:120,217,479...120,223,400
Ensembl chr 2:120,217,479...120,223,400
|
|
G |
TMEM204 |
transmembrane protein 204 |
decreases expression |
ISO |
Etoposide results in decreased expression of TMEM204 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:1,528,678...1,555,568
Ensembl chr16:1,528,688...1,555,580
|
|
G |
TMEM47 |
transmembrane protein 47 |
affects response to substance |
EXP |
TMEM47 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:34,627,075...34,657,285
Ensembl chr X:34,627,075...34,657,285
|
|
G |
TMEM97 |
transmembrane protein 97 |
affects response to substance |
EXP |
TMEM97 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:28,319,200...28,328,685
Ensembl chr17:28,319,200...28,328,685
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
multiple interactions |
EXP |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of TMPRSS2 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TMSB4X |
thymosin beta 4 X-linked |
multiple interactions decreases response to substance |
EXP |
TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein] TMSB4X protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16364925 |
|
NCBI chr X:12,975,110...12,977,223
Ensembl chr X:12,975,110...12,977,227
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
ISO |
Etoposide results in increased expression of TNF mRNA |
CTD |
PMID:15135310 PMID:18523641 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF10B |
TNF receptor superfamily member 10b |
multiple interactions increases expression |
EXP |
Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter] Etoposide results in increased expression of TNFRSF10B mRNA |
CTD |
PMID:15964798 |
|
NCBI chr 8:23,020,133...23,069,031
Ensembl chr 8:23,020,133...23,069,031
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
increases expression |
ISO |
Etoposide results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:11459812 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
TNFRSF12A |
TNF receptor superfamily member 12A |
multiple interactions increases expression |
EXP |
Estradiol inhibits the reaction [Etoposide results in increased expression of TNFRSF12A mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr16:3,020,368...3,022,383
Ensembl chr16:3,018,445...3,022,383
|
|
G |
TNFRSF14 |
TNF receptor superfamily member 14 |
increases expression |
EXP |
Etoposide results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:2,554,234...2,563,829
Ensembl chr 1:2,555,639...2,565,382
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
affects response to substance |
ISO |
TNFRSF1A protein affects the susceptibility to Etoposide |
CTD |
PMID:20159942 |
|
NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Etoposide results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:11459812 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TNFSF9 |
TNF superfamily member 9 |
increases expression |
EXP |
Etoposide results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr19:6,531,026...6,535,924
Ensembl chr19:6,531,026...6,535,924
|
|
G |
TNKS |
tankyrase |
affects response to substance |
EXP |
TNKS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:9,555,912...9,782,346
Ensembl chr 8:9,555,912...9,782,346
|
|
G |
TOP2A |
DNA topoisomerase II alpha |
affects binding decreases activity multiple interactions affects activity decreases expression increases response to substance affects response to substance decreases response to substance |
EXP ISO |
Etoposide binds to TOP2A protein Etoposide analog results in decreased activity of TOP2A protein; Etoposide metabolite results in decreased activity of TOP2A protein; Etoposide results in decreased activity of TOP2A protein [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; delphinidin results in decreased susceptibility to [Etoposide affects the activity of TOP2A protein]; Etoposide metabolite inhibits the reaction [TOP2A protein binds to Nucleic Acids, Nucleotides, and Nucleosides]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide]; TOP2A results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of TOP2A protein TOP2A protein results in increased susceptibility to Etoposide TOP2A protein modified form affects the susceptibility to Etoposide TOP2A gene mutant form results in decreased susceptibility to Etoposide; TOP2A protein mutant form results in decreased susceptibility to Etoposide |
CTD |
PMID:10856430 PMID:11325482 PMID:11470519 PMID:11531262 PMID:11676865 PMID:12569090 PMID:15211611 PMID:16969495 PMID:17575151 PMID:19182879 PMID:21056033 PMID:21413765 PMID:21878638 PMID:24650156 PMID:26198043 PMID:27422292 PMID:27533850 PMID:31512855 PMID:33760604 PMID:34635930 More...
|
|
NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896
|
|
G |
TOP2B |
DNA topoisomerase II beta |
decreases response to substance decreases activity affects response to substance decreases expression multiple interactions increases response to substance |
EXP ISO |
TOP2B protein mutant form results in decreased susceptibility to Etoposide Etoposide results in decreased activity of TOP2B protein TOP2B protein affects the susceptibility to Etoposide Etoposide results in decreased expression of TOP2B protein TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] TOP2B protein mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:10856430 PMID:15322234 PMID:16239602 PMID:17875725 PMID:26198043 PMID:27422292 More...
|
|
NCBI chr 3:25,597,905...25,664,907
Ensembl chr 3:25,597,978...25,664,909
|
|
G |
TOP3A |
DNA topoisomerase III alpha |
decreases expression |
EXP |
Etoposide results in decreased expression of TOP3A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:18,271,428...18,314,994
Ensembl chr17:18,271,428...18,315,007
|
|
G |
TOR1A |
torsin family 1 member A |
decreases expression |
EXP |
Etoposide results in decreased expression of TOR1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:129,812,942...129,824,136
Ensembl chr 9:129,812,942...129,824,244
|
|
G |
TP53 |
tumor protein p53 |
increases acetylation affects activity increases expression multiple interactions increases activity increases phosphorylation affects response to substance increases response to substance |
EXP ISO |
Etoposide results in increased acetylation of TP53 protein; Etoposide results in increased acetylation of TP53 protein mutant form Etoposide affects the activity of TP53 protein; Etoposide metabolite affects the activity of TP53 protein Etoposide results in increased expression of TRP53 protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]; Etoposide results in increased phosphorylation of and results in increased activity of TRP53 protein; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein]; TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] Etoposide results in increased activity of TP53 protein Etoposide results in increased phosphorylation of TP53 protein TRP53 protein affects the susceptibility to Etoposide 2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein; [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]; entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA]; Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein]; Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter]; Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol]; Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein]; Etoposide results in increased expression of and results in increased acetylation of TP53 protein; Etoposide results in increased phosphorylation of and affects the localization of TP53 protein; Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of TP53 protein cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein]; Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein]; Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein; Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein] TP53 protein results in increased susceptibility to Etoposide; TP53 results in increased susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:11895857 PMID:12082016 PMID:15131059 PMID:15459018 PMID:15964798 PMID:16120219 PMID:16330492 PMID:16882877 PMID:17516866 PMID:18698031 PMID:19751709 PMID:20299546 PMID:20477944 PMID:20623183 PMID:20655369 PMID:21212465 PMID:21526190 PMID:21552291 PMID:21801448 PMID:22003191 PMID:22010212 PMID:22242153 PMID:23144690 PMID:23396362 PMID:23690541 PMID:24067374 PMID:25078064 PMID:25699604 PMID:25744307 PMID:26259609 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 PMID:30177839 PMID:30818834 PMID:31542801 PMID:35435491 PMID:37956312 More...
|
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TP53BP1 |
tumor protein p53 binding protein 1 |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of TP53BP1 protein pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:26259609 PMID:27358234 |
|
NCBI chr15:43,403,061...43,510,640
Ensembl chr15:43,403,061...43,510,728
|
|
G |
TP53I3 |
tumor protein p53 inducible protein 3 |
increases expression |
EXP |
Etoposide results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 2:24,077,433...24,084,834
Ensembl chr 2:24,077,433...24,085,861
|
|
G |
TP53TG1 |
TP53 target 1 |
increases expression |
EXP |
Etoposide results in increased expression of TP53TG1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 7:87,325,347...87,345,492
Ensembl chr 7:87,322,943...87,345,560
|
|
G |
TP73 |
tumor protein p73 |
multiple interactions increases expression |
EXP |
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein]; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] Etoposide results in increased expression of TP73 mRNA; Etoposide results in increased expression of TP73 protein |
CTD |
PMID:17716971 PMID:21801448 |
|
NCBI chr 1:3,652,516...3,736,201
Ensembl chr 1:3,652,516...3,736,201
|
|
G |
TPI1 |
triosephosphate isomerase 1 |
multiple interactions increases phosphorylation |
EXP |
CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] |
CTD |
PMID:20149834 |
|
NCBI chr12:6,867,420...6,870,948
Ensembl chr12:6,867,119...6,870,948
|
|
G |
TPP2 |
tripeptidyl peptidase 2 |
multiple interactions affects localization |
EXP ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; wortmannin promotes the reaction [Etoposide affects the localization of TPP2 protein] |
CTD |
PMID:20643100 |
|
NCBI chr13:102,596,986...102,679,958
Ensembl chr13:102,596,958...102,679,958
|
|
G |
TPT1 |
tumor protein, translationally-controlled 1 |
increases expression multiple interactions |
EXP ISO |
Etoposide results in increased expression of TPT1 mRNA TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein] Etoposide results in increased expression of TPT1 mRNA; Etoposide results in increased expression of TPT1 protein TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA] |
CTD |
PMID:24067374 |
|
NCBI chr13:45,333,471...45,341,183
Ensembl chr13:45,333,471...45,341,284
|
|
G |
TRAF2 |
TNF receptor associated factor 2 |
affects response to substance |
ISO |
TRAF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:20159942 |
|
NCBI chr 9:136,881,958...136,926,607
Ensembl chr 9:136,881,912...136,926,607
|
|
G |
TRIB2 |
tribbles pseudokinase 2 |
affects response to substance |
EXP |
TRIB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:12,716,936...12,742,734
Ensembl chr 2:12,716,910...12,742,734
|
|
G |
TRIB3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of TRIB3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559
|
|
G |
TRIM2 |
tripartite motif containing 2 |
affects response to substance decreases expression |
EXP ISO |
TRIM2 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of TRIM2 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 4:153,152,163...153,339,317
Ensembl chr 4:153,152,163...153,339,319
|
|
G |
TRIM38 |
tripartite motif containing 38 |
decreases expression |
EXP |
Etoposide results in decreased expression of TRIM38 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:25,962,802...25,991,231
Ensembl chr 6:25,962,802...25,991,231
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
increases expression |
EXP |
Etoposide results in increased expression of TRPV1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411
|
|
G |
TTK |
TTK protein kinase |
decreases expression |
EXP |
Etoposide results in decreased expression of TTK mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 6:80,004,649...80,042,527
Ensembl chr 6:80,003,887...80,042,527
|
|
G |
TUBA4A |
tubulin alpha 4a |
increases expression |
EXP |
Etoposide results in increased expression of TUBA4A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:219,249,710...219,254,740
Ensembl chr 2:219,249,710...219,277,902
|
|
G |
TUFM |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Etoposide results in decreased expression of TUFM protein |
CTD |
PMID:29733421 |
|
NCBI chr16:28,842,411...28,846,348
Ensembl chr16:28,842,411...28,846,348
|
|
G |
TXN2 |
thioredoxin 2 |
decreases response to substance |
EXP |
TXN2 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:12080052 |
|
NCBI chr22:36,467,046...36,481,640
Ensembl chr22:36,467,046...36,481,640
|
|
G |
TXNIP |
thioredoxin interacting protein |
increases expression |
EXP |
Etoposide results in increased expression of TXNIP protein |
CTD |
PMID:18270325 |
|
NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579
|
|
G |
TXNL1 |
thioredoxin like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of TXNL1 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:56,597,209...56,638,592
Ensembl chr18:56,597,209...56,651,600
|
|
G |
TYMS |
thymidylate synthetase |
affects response to substance |
EXP |
TYMS gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
|
|
G |
TYRP1 |
tyrosinase related protein 1 |
affects response to substance |
EXP |
TYRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:12,693,385...12,710,285
Ensembl chr 9:12,685,439...12,710,285
|
|
G |
UBE2C |
ubiquitin conjugating enzyme E2 C |
decreases expression multiple interactions |
EXP |
Etoposide results in decreased expression of UBE2C mRNA; Etoposide results in decreased expression of UBE2C protein [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein] |
CTD |
PMID:17374387 PMID:27129209 |
|
NCBI chr20:45,812,644...45,816,952
Ensembl chr20:45,812,576...45,816,957
|
|
G |
UBL3 |
ubiquitin like 3 |
affects response to substance |
EXP |
UBL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:29,764,371...29,850,617
Ensembl chr13:29,764,371...29,850,617
|
|
G |
UCP2 |
uncoupling protein 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of UCP2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
affects response to substance increases glucuronidation |
EXP |
UGT1A1 gene polymorphism affects the susceptibility to Etoposide UGT1A1 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:12969965 PMID:17151191 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
|
|
G |
UGT1A3 |
UDP glucuronosyltransferase family 1 member A3 |
increases glucuronidation |
EXP |
UGT1A3 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:17151191 |
|
NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,042...233,773,300
|
|
G |
UGT1A8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
EXP |
UGT1A8 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:17151191 |
|
NCBI chr 2:233,617,633...233,773,300
Ensembl chr 2:233,617,633...233,773,300
|
|
G |
UNC5C |
unc-5 netrin receptor C |
increases response to substance |
EXP |
UNC5C results in increased susceptibility to Etoposide |
CTD |
PMID:21600761 |
|
NCBI chr 4:95,162,504...95,548,973
Ensembl chr 4:95,162,504...95,549,206
|
|
G |
UPP2 |
uridine phosphorylase 2 |
increases expression |
ISO |
Etoposide results in increased expression of UPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:157,995,179...158,136,154
Ensembl chr 2:157,876,702...158,136,154
|
|
G |
UTP3 |
UTP3 small subunit processome component |
decreases expression |
EXP |
Etoposide results in decreased expression of UTP3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:70,688,532...70,690,551
Ensembl chr 4:70,688,532...70,690,551
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases response to substance |
EXP |
[IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide VCAM1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
G |
VCAN |
versican |
affects response to substance |
EXP |
VCAN protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303
|
|
G |
VDAC1 |
voltage dependent anion channel 1 |
multiple interactions |
ISO |
Etoposide promotes the reaction [VDAC1 protein binds to VDAC1 protein] |
CTD |
PMID:20937774 |
|
NCBI chr 5:133,971,871...134,114,540
Ensembl chr 5:133,971,871...134,004,975
|
|
G |
VDR |
vitamin D receptor |
multiple interactions affects response to substance increases expression |
EXP |
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] VDR gene polymorphism affects the susceptibility to Etoposide; VDR intron polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:12969965 PMID:15713801 PMID:17716971 |
|
NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048
|
|
G |
VEGFA |
vascular endothelial growth factor A |
decreases response to substance |
EXP |
VEGFA mRNA results in decreased susceptibility to Etoposide |
CTD |
PMID:18494554 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VEGFC |
vascular endothelial growth factor C |
multiple interactions decreases response to substance |
EXP |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922
|
|
G |
VKORC1 |
vitamin K epoxide reductase complex subunit 1 |
increases expression |
ISO |
Etoposide results in increased expression of VKORC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:31,090,854...31,094,797
Ensembl chr16:31,090,842...31,095,980
|
|
G |
WIF1 |
WNT inhibitory factor 1 |
increases response to substance |
EXP |
WIF1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15389810 |
|
NCBI chr12:65,050,626...65,121,305
Ensembl chr12:65,050,626...65,121,305
|
|
G |
WIPI1 |
WD repeat domain, phosphoinositide interacting 1 |
affects response to substance |
EXP |
WIPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:68,421,281...68,457,496
Ensembl chr17:68,420,948...68,457,513
|
|
G |
WNT3A |
Wnt family member 3A |
increases response to substance |
EXP |
WNT3A protein results in increased susceptibility to Etoposide |
CTD |
PMID:19864107 |
|
NCBI chr 1:228,006,998...228,061,271
Ensembl chr 1:228,006,998...228,061,271
|
|
G |
WRN |
WRN RecQ like helicase |
increases response to substance |
EXP |
WRN gene mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:10725663 |
|
NCBI chr 8:31,033,810...31,176,138
Ensembl chr 8:31,033,788...31,176,138
|
|
G |
XAF1 |
XIAP associated factor 1 |
increases response to substance multiple interactions increases expression |
EXP |
XAF1 protein results in increased susceptibility to Etoposide XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] Etoposide results in increased expression of XAF1 mRNA; Etoposide results in increased expression of XAF1 protein |
CTD |
PMID:15843754 PMID:17570219 PMID:28507149 |
|
NCBI chr17:6,755,447...6,775,647
Ensembl chr17:6,755,447...6,775,647
|
|
G |
XRCC1 |
X-ray repair cross complementing 1 |
multiple interactions affects response to substance increases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 protein] XRCC1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of XRCC1 mRNA; Etoposide results in increased expression of XRCC1 protein |
CTD |
PMID:26046675 |
|
NCBI chr19:43,543,311...43,575,527
Ensembl chr19:43,543,311...43,580,473
|
|
G |
XRCC2 |
X-ray repair cross complementing 2 |
multiple interactions increases expression |
EXP |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein] |
CTD |
PMID:16417649 |
|
NCBI chr 7:152,644,776...152,676,141
Ensembl chr 7:152,644,776...152,676,193
|
|
G |
XRCC3 |
X-ray repair cross complementing 3 |
multiple interactions increases expression |
EXP |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein] |
CTD |
PMID:16417649 |
|
NCBI chr14:103,697,617...103,715,451
Ensembl chr14:103,697,609...103,715,504
|
|
G |
XRCC4 |
X-ray repair cross complementing 4 |
multiple interactions decreases response to substance increases expression |
EXP |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein] XRCC4 results in decreased susceptibility to Etoposide |
CTD |
PMID:16417649 PMID:21785230 |
|
NCBI chr 5:83,077,547...83,374,473
Ensembl chr 5:83,077,498...83,353,787
|
|
G |
XRCC5 |
X-ray repair cross complementing 5 |
affects response to substance |
EXP |
XRCC5 protein affects the susceptibility to Etoposide |
CTD |
PMID:12384553 |
|
NCBI chr 2:216,109,348...216,206,293
Ensembl chr 2:216,107,464...216,206,303
|
|
G |
ZBED1 |
zinc finger BED-type containing 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZBED1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr X:2,486,435...2,500,976 NCBI chr Y:2,486,435...2,500,976
Ensembl chr Y:2,486,414...2,500,976 Ensembl chr X:2,486,414...2,500,976
|
|
G |
ZBTB24 |
zinc finger and BTB domain containing 24 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZBTB24 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:109,462,594...109,483,219
Ensembl chr 6:109,460,632...109,483,239
|
|
G |
ZDHHC11 |
zinc finger DHHC-type containing 11 |
affects response to substance |
EXP |
ZDHHC11 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:795,605...860,563
Ensembl chr 5:795,605...858,973
|
|
G |
ZFP36L1 |
ZFP36 ring finger protein like 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZFP36L1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr14:68,787,655...68,796,243
Ensembl chr14:68,787,660...68,796,253
|
|
G |
ZMAT3 |
zinc finger matrin-type 3 |
increases expression |
EXP |
Etoposide results in increased expression of ZMAT3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:179,017,223...179,072,513
Ensembl chr 3:178,960,121...179,072,215
|
|
G |
ZNF200 |
zinc finger protein 200 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZNF200 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr16:3,222,325...3,235,158
Ensembl chr16:3,222,325...3,236,221
|
|
G |
ZNF202 |
zinc finger protein 202 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZNF202 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr11:123,723,914...123,741,660
Ensembl chr11:123,723,914...123,741,675
|
|
G |
ZNF232 |
zinc finger protein 232 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZNF232 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:5,105,734...5,123,116
Ensembl chr17:5,105,269...5,123,162
|
|
G |
ZNF32 |
zinc finger protein 32 |
affects response to substance |
EXP |
ZNF32 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:43,643,862...43,648,881
Ensembl chr10:43,643,860...43,648,881
|
|
G |
ZNF365 |
zinc finger protein 365 |
increases expression |
ISO |
Etoposide results in increased expression of ZFP365 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:62,643,643...62,672,010
Ensembl chr10:62,520,448...62,672,011
|
|
G |
ZNF45 |
zinc finger protein 45 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZNF45 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr19:43,912,624...43,935,282
Ensembl chr19:43,912,624...43,935,282
|
|
G |
ZNF544 |
zinc finger protein 544 |
decreases expression |
EXP |
Etoposide results in decreased expression of ZNF544 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr19:58,228,914...58,277,455
Ensembl chr19:58,228,594...58,277,495
|
|
G |
ZNF750 |
zinc finger protein 750 |
increases expression |
ISO |
Etoposide results in increased expression of ZFP750 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:82,829,434...82,840,022
Ensembl chr17:82,829,434...82,840,022
|
|